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Abstract
Modern medical treatments have substantially improved cure rates for many chronic
diseases and have generated increasing interest in appropriate statistical models to
handle survival data with non-negligible cure fractions. The mixture cure models
are designed to model such data set, which assume that the studied population is a
mixture of being cured and uncured. In this dissertation, I will develop two programs
named smcure and NPHMC in R. The first program aims to facilitate estimating two
popular mixture cure models: the proportional hazards (PH) mixture cure model and
accelerated failure time (AFT) mixture cure model. The second program focuses on
designing the sample size needed in survival trial with or without cure fractions based
on the PH mixture cure model and standard PH model. The two programs have been
tested by comprehensive simulation settings and real data analysis. Currently, they
are available for download from R CRAN. The third project in my dissertation will
focus on developing a new estimation method for the PH mixture cure model with
allowing patients to die from other causes. The performance of proposed method has
been evaluated by extensive simulation studies.
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Chapter 1
Introduction
One of the most important statistical models in handling survival data is the Cox
proportional hazards (PH) model. A common unstated assumption behind this model
is that all patients will eventually experience the event of interest, given that the
follow-up time is long enough. However, with the development of medical studies,
more and more fatal diseases are now curable. Therefore, in some clinical studies,
a substantial proportion of patients may never experience the event because the
treatment has effectively cured the patients. Statistically speaking, an estimated
Kaplan-Meier survival curve will tend to level off at a value greater than 0 after a
certain time. That is, after sufficient follow-up, the survival curve will reach a plateau.
We refer to these subjects who never experience the event as cured (nonsuscepti-
ble) and the remaining subjects as uncured (susceptible). The main interests of such
data are to determine the proportion of cured patients, the failure time distribution
of uncured patients, and the possible effects of covariates.
In this chapter, we will introduce two examples of data with cure fractions in
Section 1.1. The first data is melanoma data from Eastern Cooperative Oncology
Group (ECOG) and the second one is leukemia data from Bone Marrow Transplant
study. The two basic survival regression models: the PH model and AFT model will
be discussed in Section 1.2. In Section 1.3, we will give the outline of this dissertation.
1
1.1 Motivation
Eastern Cooperative Oncology Group (ECOG) Data
We consider melanoma data from the ECOG phase III clinical trial E1684 [16]. This
study has been investigated by many authors [16, 6, 5, 11, 8]. The aim of the E1684
clinical trial was to evaluate the high dose interferon alpha-2b (IFN) regimen against
the placebo as the postoperative adjuvant therapy on relapse-free survival (RFS)
in patients with American Joint Committee on Cancer (AJCC) stage IIB or III
melanoma.
A total of 287 patients with high-risk melanomas were accrued to E1684 be-
tween 1984 and 1990. High-risk patients were defined to include those designated as
stage IIB or III by the former AJCC staging system (primary tumor >4 mm depth
with or without regional lymph node involvement or shallower lesions with patho-
logically proven lymphatic metastases or regional lymph node recurrence). Patients
were treated with wide local excision and complete regional lymph node dis-section
and then randomized to adjuvant high dose IFN (20 MU/m IV 5 days per week for 4
weeks, followed by 10 MU/m 3 days per week SC for 48 weeks) or observation group.
The results of this trial were first reported in 1996 with a median follow-up time of
6.9 years (range, 0.6 to 9.6 years) [16]. After deleting 2 observations with missing
data, analysis of treatment effects versus observation group was based on data from
285 patients randomized to IFN or observation group in trial E1684. The median
RFS was 1.721 years in the IFN arm versus 0.982 year in the observation arm with
a p-value of 0.0118 by log-rank test. The IFN treatment group is coded as 1 and
observation group as 0. The response variable is RFS in years.
The time data is listed in Table 1.1. There were 140 patients in observation
group and 145 patients in IFN treatment group. The Kaplan-Meier survival curves
for the IFN treatment group and observation group are given in Figure 1.1. The
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RFS is significant better for IFN group compared to the observation group (p-value
= 0.0118 by log rank test).
Figure 1.1 Kaplan-Meier relapse-free survival for the IFN treatment group and the
control group.
From the Kaplan-Meier survival curves, we can see that the estimated RFS curve
from the IFN group is above the observation group, which indicates that the survival
probability of patients from the IFN group is higher than that from the observation
group. It also shows that both curves level off at a value substantially greater than 0
after about 8-year follow-up, which indicates that some patients will not experience
the recurrence after treatments. Therefore, there may exist cured patients in both
treatment group and observation group.
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Table 1.1 ECOG 1684
High-dose
interferon
alfa-2b
(IFN)
0.04932, 0.06027, 0.09863, 0.10411, 0.11507, 0.12329, 0.13151,
0.13151, 0.14247, 0.14521, 0.15890, 0.17260, 0.17260, 0.18082,
0.18082, 0.19178, 0.24658, 0.26027, 0.26027, 0.26027, 0.30137,
0.30137, 0.33699, 0.34247,0.34795, 0.35616, 0.39178, 0.41370,
0.43836, 0.43836, 0.46027, 0.46027, 0.47945, 0.49041, 0.49041,
0.54795, 0.55068, 0.55068, 0.56164, 0.56986, 0.59178, 0.60822*,
0.62466, 0.63288, 0.64384, 0.64658, 0.70959, 0.78630, 0.82466,
0.82740, 0.82740, 0.85479, 0.85753, 0.86301, 0.95068, 0.99726,
1.00274, 1.00822, 1.02192, 1.03288, 1.07123, 1.09041, 1.15068,
1.16438, 1.19178, 1.23836, 1.35068, 1.47671, 1.48767, 1.52055,
1.61370, 1.70411, 1.72055, 1.73425, 1.83562*, 1.85753, 1.88219,
2.08219, 2.15068*, 2.28219, 2.29589, 2.31507, 2.47671, 2.55068,
2.55616, 2.87397, 2.87671, 2.90411*, 3.02466, 3.05479, 3.58630,
3.93973, 4.26301, 4.29041, 4.29863*, 4.36164*, 4.63836*, 4.81918*,
4.86027*, 4.89315*, 4.90685*, 4.92877*, 4.94795*, 5.16712,
5.30137, 5.45479*, 5.54521*, 5.59178*, 5.75890*, 6.00000*,
6.13699*, 6.20274*, 6.34795*, 6.37808*, 6.41096*, 6.47123*,
6.89315*, 7.00000*, 7.04110*, 7.04384*, 7.23288*, 7.30685*,
7.35616*, 7.41918*, 7.42466*, 7.62192*, 7.70959*, 7.82192*,
7.83562*, 7.96438*, 7.96712*, 8.04110*, 8.09863*, 8.21370*,
8.28767*, 8.33425*, 8.36712*, 8.40000*, 8.45753*, 8.75342*,
8.98630*, 8.99178*, 9.03288*, 9.38356*,9.63014*
Placebo 0.03288, 0.06027, 0.06027, 0.07671, 0.07945, 0.08493, 0.09589,
0.09863, 0.09863, 0.10685, 0.10959, 0.12603, 0.12603, 0.12877,
0.13151, 0.13973, 0.13973, 0.14795, 0.14795, 0.15342, 0.17260,
0.17260, 0.18630, 0.19452, 0.19452, 0.21918, 0.23014, 0.23288,
0.23836, 0.24110, 0.24110, 0.24110, 0.25753, 0.26575, 0.26575,
0.28767, 0.28767, 0.28767, 0.28767, 0.30959, 0.30959, 0.32055,
0.32055, 0.32603, 0.32877, 0.34795, 0.35616, 0.36438, 0.38630,
0.41096, 0.41644, 0.43562, 0.44384, 0.45205, 0.45479, 0.46301,
0.46575, 0.49589, 0.51507, 0.51507, 0.52603, 0.57260, 0.59726,
0.62740, 0.72603, 0.89589, 0.90137, 0.91781, 0.92877, 0.97808,
0.98630, 0.98904, 1.00822, 1.01644, 1.06849, 1.08219, 1.18904,
1.35342, 1.35616, 1.51507, 1.64110, 1.65205, 1.69589, 1.69863,
1.70959, 1.83288, 1.84658, 1.87945, 1.89863*, 1.94795, 2.09041,
2.13151, 2.39726, 2.57808, 2.72329, 3.06849, 3.18630, 3.20548,
3.27671, 3.33973, 3.85205, 3.86575, 4.24384*, 4.40822*, 4.45205,
4.72055*, 4.74795*, 4.76986*, 4.81370*, 4.86849, 4.95616*,
5.12329*, 5.24658*, 5.32329*, 5.77808*, 5.88493*, 6.01096,
6.02192*, 6.06575*, 6.15890*, 6.30959*, 6.40548*, 6.48493*,
6.51507*, 6.85479*, 6.93151*, 7.09589*, 7.25205*, 7.53151*,
7.63836*, 7.79726*, 7.81370*, 7.83288*, 7.94521*, 7.99726*,
8.02740*, 8.24658*, 8.26301, 8.34247*, 9.64384*
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Bone Marrow Transplant Study for Leukemia Patients
We consider the bone marrow transplant study for the refractory acute lymphoblastic
leukemia patients, which was first analyzed by [15]. This data set is widely used in
the AFT mixture cure model because the PH assumption is not appropriate for
the latency distribution [31]. Figure 1.2 illustrates the logarithm of the estimated
cumulative hazard functions for the uncensored patients for each group based on the
Nelson-Aalen estimator. It is easy to see that the two curves cross over which indicate
that the PH assumption is not appropriate for this data set.
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Figure 1.2 Logarithm of the cumulative hazard function curves. Dashed line for
the autologous transplant, solid line for the allogeneic transplant.
There were 46 patients in the allogeneic treatment and 44 patients in the autol-
ogous treatment group. The treatment variable is included in both incidence and
latency parts (1 for autologous treatment group; 0 for allogeneic treatment group).
The data set is listed in Table 1.2, and the Kaplan-Meier survival curves for the two
treatment groups are given in Figure 1.3.
5
Table 1.2 Bone marrow transplant treatment of high risk acute lymphoblastic
leukemia (March 1982–December 1985, University of Minnesota).
allogeneic
treatment
group
11, 14, 23, 31, 32, 35, 51, 59, 62, 78, 78, 79, 87, 99, 100, 141,
160, 166, 216, 219, 235, 250, 270, 313, 332, 352, 368, 468, 491,
511, 557, 628*, 726*, 819, 915*, 966*, 1109*, 1158*, 1256, 1614*,
1619*, 1674*, 1712*, 1745*, 1820*, 1825*
autologous
treatment
group
21, 40, 42, 50, 53, 54, 56, 61, 64, 67, 73, 76, 79, 81, 88, 95, 98, 98,
99, 104, 105, 106, 112, 131, 147, 171, 172, 179, 189, 195, 199, 213,
223, 224, 277, 724*, 729*, 734, 1053*, 1094*, 1192*, 1475*, 1535*,
1535*, 1845*
Figure 1.3 Kaplan-Meier survival for Bone Marrow Transplant Study.
From the Kaplan-Meier survival curves, we can see that the estimated survival
curve from the allogeneic treatment group is above the one from the autologous
treatment group, which indicates that the survival probability of patients from the
allogeneic treatment group is higher than that from the autologous treatment group
(p-value = 0.106 by log-rank test). It also shows that both curves level off at a value
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substantially greater than 0 after one or two years follow-up, which indicates that
some patients will not experience the recurrence after the treatments. Therefore,
there may exist cured patients in both treatment groups.
Both data display the possible cure fractions, in order to estimate the proportion
of cured patients accurately, a cure rate model has to be considered. The most
commonly used type of cure rate model is the mixture cure model which was first
developed by Boag in 1949 [2] and later developed by Berkson and Gage in 1952 [1].
After that, there are many extensions on the mixture cure model, such as the PH
mixture cure model and AFT mixture cure model. In this dissertation, we will focus
on the software developments and advanced methodology developments in various
mixture cure models.
1.2 Basic Survival Regression Models
Standard PH Model
The PH assumption provides a way to introduce covariates into models and to sep-
arate the effect of the covariates and the shape of a baseline hazard function. It has
been successfully employed in Cox’s PH regression model for survival data. The PH
model can be expressed as
h(t) = h0(t) exp(βx), (1.1)
where h(·) is the hazard function, h0(·) is the baseline hazard function and β is a
vector of unknown coefficients of interest. If x = 0, the hazard function h(t) is equal
to the baseline hazard function h0(t). The model is called the proportional hazards
model because if we look at two individuals with covariate values x1 and x2, the ratio
of their hazards
h(t|x1)
h(t|x2) = exp(β(x1 − x2)),
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is a constant. Therefore, the hazards are proportional. The quantity exp(β(x1−x2))
is called as the relative risk (hazard ratio) of an individual with risk factor x1 having
the event as compared to an individual with risk factor x2. In particular, if x1
indicates the treatment effect (x1 = 1 if treatment and x1 = 0 if placebo) and all
other covariates have the same value, exp(β) is the relative risk between patients
in the treatment group and control group with other risks factors fixed at the same
value.
The cumulative hazards function is defined as the integral of the baseline hazard
function. If H(t) is the cumulative hazards function corresponding to h(t), H(t) =∫∞
0 h(t)dt. Let H(t) and H0(t) be the cumulative hazards functions corresponding to
h(t) and h0(t). The logarithm of the cumulative hazard function satisfies the following
equation
log(H(t)) = βx + log(H0(t)).
Therefore, the curves of the logarithm of the cumulative hazard function for various
levels of x should be parallel, which is referred to as the PH assumption. Usually,
this assumption should be verified before using the PH model.
The main innovation of the PH model is that β can be estimated without speci-
fying, or even estimating, a baseline hazard function. This is accomplished by devel-
oping the concept of the partial likelihood, a likelihood function which only depends
on β. In the rest of this section, we will introduce the partial likelihood estimation
method of the PH model. Let O = (ti, δi,xi) denote the observed data for the ith
individual i = 1, · · · , n, where ti is the observed survival time, δi is the censoring
indicator with δi = 1 for the uncensored time and 0 for the censored time, and xi is
the value of covariate. We assume that censoring is noninformative in that, given xi,
the event and censoring time for the ith patient are independent.
Suppose that there are no ties among event times. Let t1 < t2 < · · · < tD denote
the ordered event times and x(i)k be the kth covariate associated with the individual
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whose failure time is ti. Define the risk set at time ti, R(ti), as the set of all individuals
who are still under study at a time just prior to ti. The partial likelihood for the PH
model is expressed by
L(β) =
D∏
i=1
exp[∑pk=1 βkx(i)k]∑
j∈R(ti) exp[
∑p
k=1 βkxjk]
.
This is treated as a usual likelihood, and inference is carried out by usual means. It
is of interest to note that the numerator of likelihood depends only on information
from the individual who experiences the event, whereas the denominator utilizes
information about all individuals who have not yet experienced the event (including
some individuals who will be censored later).
Let LL(β) = ln[L(β)], we can write LL(β) as
LL(β) =
D∑
i=1
p∑
k=1
βkx(i)k −
D∑
i=1
ln
 ∑
j∈R(ti)
exp
( p∑
k=1
βkxjk
) .
The efficient score equation is found by taking partial derivatives with respect to β
as follows. Let Ub(β) = ∂LL(β)/∂βb, b = 1, . . . , p. Then,
Ub(β) =
D∑
i=1
x(i)b −
D∑
i=1
∑
j∈R(ti) xjb exp[
∑p
k=1 βkxjk]∑
j∈R(ti) exp[
∑p
k=1 βkxjk]
The partial maximum likelihood estimates are found by maximizing LL(β). This
maximization procedure can be done in most statistical software packages, such as
coxph in R and PROC PHREG in SAS.
Standard AFT Model
The AFT model regresses the logarithm of survival time over covariates, which is a
useful alternative to the PH model, when the PH assumption does not satisfy. We
can specify the AFT model by
log(T ∗i ) = βxi + εi , (1.2)
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where εi’s are independent random errors and E(εi) may not be zero. One advantage
of the AFT model over the PH model is that the covariate effects on the failure
time are modeled directly rather than indirectly, as in the PH model. Thus, the
interpretation of covariate effects in the AFT model is much simpler than in the PH
model.
There are many discussions on parametric estimation methods [18, 13] and semi-
parametric estimation methods [28, 23] for the AFT model. Our main interest focuses
on the semiparametric estimation method. Tsiatis [28] proposed the rank estimation
method and Ritov [23] considered the general linear square estimation method. How-
ever, Ritov[23] proved the equivalency between the rank estimation method and the
general linear square estimation method.
In the rest of this section we will give a brief description of the rank estimation
method in the semiparametric AFT model. The rank estimation method can be
derived from the partial likelihood principle of the PH model. Consider the usual PH
model with the regression coefficient vector γ, say
h(εi) = h0(εi) exp(γ′xi),
where εi = log ti − βxi. The partial log likelihood function is
n∑
i=1
δi
(
γ′xi − log
n∑
j=1
eγxjI(εj ≥ εi)
)
,
where I(·) is the indicator function. The derivative of the logarithm of the partial
likelihood function with respect to γ is simply:
Ψ(γ) =
n∑
i=1
δi
(
xi −
∑n
j=1 xjeγxjI(εj ≥ εi)∑n
j=1 e
γxjI(εj ≥ εi)
)
.
If the parameter γ is 0, Ψ(0) = 0 can be used as a linear rank estimating equation for
β (εi is a function of β). It is important to note that as long as the underlying failure
times T ∗i are independent and identically distributed, for large n, Ψ(0) is approxi-
mately centered around 0. It can also be extended to include a general (predictable)
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weight function. That is, we rewrite Ψ(0) as Ψ(β; k(·)):
Ψ(β; k(·)) =
n∑
i=1
δik(εi)
(
xi −
∑n
j=1 xjI(εj ≥ εi)∑n
j=1 I(εj ≥ εi)
)
,
where k(·) is a general (predictable) weight function. For example, k(u)
= ∑nj=1 I(εj ≥ u)/n is called as the Gehan weight function. Once the weight function
is specified, Ψ(β) = 0 is the estimating equation for β.
However, the above semiparametric estimating functions are step functions of
the regression parameters with potentially multiple roots, and the corresponding
estimators may not be well defined. Jin[12] provided simple and reliable methods
for implementing the aforementioned rank estimators. They showed that the rank
estimator with the Gehan weight function can be readily obtained by minimizing a
convex objective function through a standard linear programming technique. Their
procedure yielded a consistent root and can be extended to other choices of weight
function. Under the Gehan weight function, Jin[12] showed that Ψ(β; k(·)) can be
simplified as
n−1
n∑
i=1
n∑
j=1
δi(xi − xj)I(εj ≥ εi) ,
which is the gradient of the convex function
n−1
∑
i
∑
j
δi (εi − εj) I(εi ≤ εj) .
Therefore it can be easily minimized by the linear programming method.
1.3 Outline of Dissertation
In Chapter 2, we will outline the PH mixture cure model and its computational
estimation method. In the mixture cure model, the smcure package is developed
to estimate the semiparametric PH mixture cure model with covariates where the
cure fraction can be modeled by various binary regression models and the survival
of uncured individuals can be modelled by the PH survival model. The R function
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of the smcure package and its usage are also described. The results of simulation
study are provided to evaluate the performance of the package. An example is given
to illustrate the usage of the package.
In Chapter 3, we will focus on the sample size design of a study with possible long-
term survivors based on the PH mixture cure model. An R package NPHMC will be
introduced. This package is developed to facilitate physicians or clinicians to design
a study with or without cure fraction based on the semiparametric PH mixture cure
model or standard PH model. The parameters of sample size formula can be specified
based on previous literature reviews or estimated based on historical or observed data
via smcure R package.
In Chapter 4, we will propose a new estimation method for PH mixture cure
model allowing other causes of death. with competing risks data. The model and
its computational method will be discussed. The results of simulation study and
application to real data analysis will also be provided.
In Chapter 5, the cure rate model will be extended to the AFT mixture cure model.
When the PH assumption does not satisfy for the uncured patients, an AFT model
is an alternative to model the latency party of mixture cure model. The estimation
method and its application in R will also be discussed.
Chapter 6 is the summary and conclusions of mixture cure models. Some future
work will also be discussed.
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Chapter 2
Estimating Semiparametric PH Mixture Cure
Model and Software Program Development
2.1 Abstract
The mixture cure model is a special type of survival models and it assumes that the
studied population is a mixture of uncure (susceptible) individuals who may expe-
rience the event of interest, and cure (non-susceptible) individuals who will never
experience the event. For such data, standard survival models are usually not appro-
priate because they do not account for the possibility of cure. The mixture model
has been widely used in medical research. The aim of this chapter is to present the
PH mixture cure model and an R package smcure, which fits the PH mixture cure
model semiparametrically.
2.2 Introduction
The PH model is the most popular model in survival analysis. As stated before, the
common unstated assumption behind this model is that all patients will eventually
experience the event of interest, given that the follow-up time is long enough. How-
ever, in recent years, with the development of medical studies, more and more fetal
diseases are now cured. There has been an increasing interest in modelling survival
data with long term survivors. Such data often arise from clinical trials. Thus, there
is a need to develop statistical models to analyze whether the treatment can cure the
disease or slow down the progression of the disease if not cure.
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The mixture cure model, firstly introduced by Boag (1949) [2] and Berkson and
Gage (1952)[1], is one of the popular models to estimate the cure rate of the treatment
and the survival rate of uncure patients at the same time.
Let T denote the failure time of interest, 1− pi(z) be the probability of a patient
being cured depending on z, and S(t|x) be the survival probability of the uncured
patients depending on x, where x and z are observed values of two covariate vectors
that may affect the survival function. The mixture cure model can be expressed as
Spop(t|x, z) = pi(z)S(t|x) + 1− pi(z) (2.1)
Usually, pi(z) is refer to as “incidence" and S(t|x) is refer to as “latency". If the PH
model is used to model the latency part, the cure model is called the PH mixture
cure model.
An R package called smcure is developed to estimate semiparametric PH mixture
cure model and semiparametric AFT mixture cure model. This chapter will only
focus on PH mixture cure model and AFT mixture cure model will be discussed in
Chapter 5.
In section 2.3, we outline models and the computational methods. The R function
and its arguments are described in Section 2.4. Simulation results are displayed in
Section 2.5. We use an example to illustrate the smcure package in Section 2.6.
2.3 Model and Computational Method
Semiparametric PH Mixture Cure Model
An advantage of the mixture cure model is that the proportion of cured subjects
and the survival distribution of uncured subjects are modeled separately and the
interpretation of effects of x and z is straightforward.
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Usually, a logit link function
pi(z) = exp(bz)1 + exp(bz) ,
where b is a vector of unknown parameters, is used to model the effects of z. Other
link functions can also be applied to the incidence part, such as the complementary
log-log link
log(− log(1− pi(z))) = bz,
and the probit link
Φ−1(pi(z)) = bz,
where Φ(·) is the cumulative distribution function of a standard normal distribution.
The logit link is a default option in the smcure package.
If the distribution of failure time of uncured patients/latency part can be modeled
by a PH model, the mixture cure model is called as the PH mixture cure model.
To model the effect of covariates x on the failure time distribution of uncured
patients in the mixture model, we employ the PH assumption to model the effect of
x on the distribution by h(t) = h0(t) exp(βx). This assumption implies that S(t|x) =
S0(t)exp(βx) where S0(t) is the baseline survival function of uncured subjects when x =
0. Parametric approaches to the mixture cure model were studied by many authors
[10, 21, 30]. Since it is usually difficult to verify a parametric assumption, there has
been increasing interest in the semiparametric mixture cure models [19, 20, 26, 27, 31].
This chapter will focus on semiparametric estimation method for the PH mixture cure
model.
Computational Method
Let O = (ti, δi, zi,xi) denote the observed data for the ith individual i = 1, · · · , n,
where zi,xi are the possible covariates in the incidence and latency parts respectively.
We assume that the censoring is independent and noninformative. It is worthwhile
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pointing out that the same covariates are allowed for the incidence and latency com-
ponents although we use different covariate notations for these two components.
Let Θ = (b,β, S0(t)) denote the unknown parameters. To use the EM algorithm
to estimate unknown parameters in this PH mixture cure model, let yi be an indicator
of cure status of the ith patient, namely, yi = 1 if the patient is uncured and 0 other-
wise, i = 1, 2, · · · , n.. Obviously, if δi = 1, yi = 1; if δi = 0, yi is not observable and it
can be one or zero. Note that pi(z) = P (yi = 1|z). Let y = (y1, y2, · · · , yn). Therefore,
y is partially missing information which will be employed in the EM algorithm.
Given y = (y1, y2, · · · , yn) and O, the complete likelihood function can be ex-
pressed as
n∏
i=1
[1− pi(zi)]1−yipi(zi)yih(ti|Y = 1,xi)δiyiS(ti|Y = 1,xi)yi (2.2)
where h(·) is the hazard function corresponding to S(·). The logarithm of the com-
plete likelihood function can be written as lc(b,β; O,y) = lc1(b; O,y) + lc2(β; O,y),
where
lc1(b; O,y) =
n∑
i=1
yi log[pi(zi)] + (1− yi) log[1− pi(zi)], (2.3)
lc2(β; O,y) =
n∑
i=1
yiδi log[h(ti|Y = 1,xi)] + yi log[S(ti|Y = 1,xi)]. (2.4)
The E-step in the EM algorithm computes the conditional expectation of the
complete log-likelihood with respect to y′is, given the observed data O and current
estimates of parameters Θ(m) = (b(m),β(m), S(m)0 (t)). The conditional expectation of
yi will be enough to complete this step since both (2.3) and (2.4) are linear functions
of yi. The expectation of E(yi|O,Θ(m)) can be written as
w
(m)
i = E(yi|O,Θ(m)) = δi + (1− δi)
pi(zi)S(ti|Y = 1,xi)
1− pi(zi) + pi(zi)S(ti|Y = 1,xi)
∣∣∣∣∣
(O,Θ(m))
. (2.5)
It is easy to see that w(m)i = 1 if δi = 1 and w
(m)
i is the probability of uncured
patients if δi = 0. Thus, the second part of E(yi|O,Θ(m)) can be interpreted as the
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conditional probability of the ith individual remaining uncured. Because δi logw(m)i =
0 and δiw(m)i = δi, the expectations of (2.3) and (2.4) can be written as
E(lc1) =
n∑
i=1
w
(m)
i log[pi(zi)] + (1− w(m)i ) log[1− pi(zi)], (2.6)
E(lc2) =
n∑
i=1
δi log[w(m)i h(ti|Y = 1,xi)] + w(m)i log[S(ti|Y = 1,xi)]. (2.7)
The M-step in the EM algorithm is to maximize (2.6) and (2.7) with respect to
the unknown parameters. The parameters in equation (2.6) can be easily estimated
by ‘glm’ package in R. Because the expressions of equation (2.7) and w(m)i depend on
the latency assumption, we will first demonstrate the estimation approach under the
PH mixture cure model.
Peng and Dear [22] and Sy and Taylor [26] proposed a partial likelihood type
method to estimate β without specifying the baseline hazard function. The estimating
equation (2.7) can be written as
log
n∏
i=1
[h0(ti) exp(βxi + log(w(m)i ))]δiS0(ti)exp(βxi+log(w
(m)
i )), (2.8)
which is similar to the log-likelihood function of the standard PH model with the
additional offset variable log(w(m)i ). Therefore, the parameters in equation (2.7) can
be estimated by ‘coxph’ package in R. A detailed presentation can be found in Peng
[20], Peng and Dear [22], and Sy and Taylor [26].
Estimation of the Survival Function in the E-Step
In the E-step, we update wi by (2.5). This updating involves the survival function
S(t|Y = 1), which also involves the baseline survival function S0(t|Y = 1) for given
βˆ. Therefore, the estimation method of baseline survival function S0(t|Y = 1) based
on the current information is needed to complete the E-step.
Let t(1) < t(2) < · · · < t(k) be the distinct uncensored failure times, dt(j) denote
the number of events and R(t(j)) denote the risk set at time t(j). The Breslow-type
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estimator for S0(t|Y = 1) is given by
Sˆ0(t|Y = 1) = exp
− ∑
j:t(j)≤t
dt(j)∑
i∈R(t(j))w
(m)
i e
βxi
 . (2.9)
Because the estimator, Sˆ0(t|Y = 1), may not approach 0 as t→∞, we set Sˆ0(t|Y =
1) = 0 for t > t(k). Then Sˆ(t|Y = 1) = Sˆ0(t|Y = 1)exp(βˆx).
Variance Estimation
Because of the complexity of the estimating equation in the EM algorithm, the stan-
dard errors of estimated parameters are not directly available. In order to obtain the
variance of βˆ and bˆ, this package uses sample function in R to respectively draw
random bootstrap samples with replacement from cases and controls. The results of
standard errors with different bootstrap sampling numbers for the later two examples
are shown in Tables 2.1 and 2.2.
Table 2.1 Eastern Cooperative Oncology Group (ECOG) Data
Cure probability model SE(nboot=100) SE(nboot=200) SE(nboot=500)
Intercept 0.35 0.33 0.29
TRT 0.36 0.33 0.31
SEX 0.34 0.33 0.33
AGE 0.02 0.01 0.01
Failure time distribution model SE(nboot=100) SE(nboot=200) SE(nboot=500)
TRT 0.16 0.17 0.17
SEX 0.18 0.17 0.19
AGE 0.01 0.01 0.01
Table 2.2 Bone Marrow Transplant Study
Cure probability model SE(nboot=100) SE(nboot=200) SE(nboot=500)
Intercept 0.25 0.23 0.26
TRT 0.52 0.48 0.54
Failure time distribution model SE(nboot=100) SE(nboot=200) SE(nboot=500)
Intercept 0.21 0.18 0.18
TRT 0.30 0.27 0.27
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2.4 Package Description
The estimation methods discussed above are implemented in the smcure package.
The smcure function in the package can be called with the following syntax:
smcure(formula,cureform,offset=NULL,data,na.action=na.omit,
model=c("ph","aft"),link="logit",Var=TRUE,emmax=50,eps=1e-7,nboot=100)
The required arguments are:
• formula: a formula object, with the response on the left of a ’∼’ operator, and
the variables included in the latency part on the right. The response must be
a survival object as returned by the Surv function.
• cureform: specifies the variables included in the incidence part on the right of
a ’∼’ operator.
• data: a data frame containing variables used in formula and cureform.
• model: specifies survival model in the latency component, which can be "ph"
or "aft".
The optional arguments are:
• offset: variable(s) with coefficient 1 in both incidence and latency parts of the
semiparametric PH mixture cure model or the semiparametric AFTMC model.
By default, offset = NULL.
• na.action: a missing-data filter function. By default na.action = na.omit.
• link: specifies the link function in the incidence component. The logit, probit or
complementary loglog (cloglog) links are available. By default link = "logit".
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• Var: if it is TRUE, the program returns bootstrap standard errors Std.Error for
βˆ and bˆ by the bootstrap method. If it is set to be False, the program only
returns coefficient estimates. By default, Var = TRUE.
• emmax: specifies the maximum iteration number. If the convergence criterion
is not met, the EM iteration will be stopped after emmax iterations and the
estimates will be based on the last maximum likelihood iteration. The default
emmax = 50.
• eps: sets the convergence criterion. The default is eps = 1e-7. The itera-
tions are considered to be converged when the maximum relative change in the
parameters and likelihood estimates between iterations is less than the value
specified.
• nboot: specifies the number of bootstrap samplings. The default nboot = 100.
The output is composed of two parts: Cure probability model and Failure
time distribution model. The cure rate can be easily estimated from the output
by 1 − pˆi(z). The estimated mixture cure survival function Spop(·) is computed by
predictsmcure function and plotted by plotpredictsmcure function.
Notes of the package:
• The user has to create “dummy variables" outside the package if data has cat-
egorical variable with more than two values.
• The “formula" and “cureform" arguments require at least one covariate.
• The default nboot = 100 is good number to estimate variance. From the Tables
2.1 and 2.2, we can see that the impact of the choice of 100, 200 and 500 for
the nboot is trivial.
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2.5 Simulation Study
In the simulation study, the probability of cure is generated from a logistic model
where pi(z) = exp(bz)1+exp(bz) . The covariate z is generated from a binary distribution
with a probability of 0.5. Censoring times are generated from a uniform distribution
U(c1, c2), where constants of c1 and c2 are determined to obtain a desired censoring
rate. The survival times of uncure patients are generated from either a Weibull
distribution where S(t|Y = 1, z) = exp[−(λt)k exp(βz)] with λ = 0.5 and k = 1 or a
Lognormal distribution of log N(0,1). The results below are based on n = 200 and
n = 500 respectively with 500 replications.
Table 2.3 Estimates from PHMC model (2,-1,2)
Survival Censoring Parameter True n = 200 n = 500
Distribution Rate Values Bias MSE Bias MSE
Weibull 21.9 bˆ0 2 0.0644 0.1530 0.0470 0.0505
bˆ1 -1 -0.0590 0.2092 -0.0459 0.0693
βˆ1 2 0.0185 0.0514 0.0077 0.0199
33.4 bˆ0 2 -0.4613 0.9757 -0.5052 0.4038
bˆ1 -1 0.4856 1.0264 0.5102 0.4299
βˆ1 2 0.0982 0.0328 0.0881 0.0218
Lognormal 21.1 bˆ0 2 0.0655 0.1407 0.0318 0.0475
bˆ1 -1 -0.0459 0.1885 -0.0351 0.0675
βˆ1 2 0.0238 0.0461 0.0139 0.0190
29.5 bˆ0 2 -0.2903 0.5530 -0.3329 0.2270
bˆ1 -1 0.3022 0.5905 0.3280 0.2429
βˆ1 2 -0.0626 0.0584 -0.0695 0.0279
Tables 2.3 and 2.4 present the estimated biases and MSE from the PH mixture
cure model of three regression parameters b0, b1 and β1 based on the logistic-Weibull
data and logistic-lognormal data.
In Table 2.3, b0 = 2 and b1 = −1 correspond to pi(z = 0) = 0.88 and pi(z =
1) = 0.73 which mean that 12% of the population is cured in the control group and
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Table 2.4 Estimates from PHMC model (1.3863,-1,2)
Survival Censoring Parameter True n = 200 n = 500
Distribution Rate Values Bias MSE Bias MSE
Weibull 32.1 bˆ0 1.3863 0.0638 0.0923 0.0123 0.0291
bˆ1 -1 -0.0566 0.1384 -0.0115 0.0473
βˆ1 2 0.0092 0.0615 0.0135 0.0225
37.5 bˆ0 1.3863 0.0714 0.9070 -0.0216 0.0773
bˆ1 -1 -0.0713 0.9791 0.0125 0.0945
βˆ1 2 0.0041 0.0667 -0.0024 0.0260
Lognormal 32.0 bˆ0 1.3863 0.0265 0.0846 0.0163 0.0325
bˆ1 -1 -0.0209 0.1358 -0.0067 0.0510
βˆ1 2 0.0330 0.0594 0.0193 0.0262
39.4 bˆ0 1.3863 -0.1662 0.2517 -0.2246 0.1238
bˆ1 -1 0.1706 0.3061 0.2362 0.1448
βˆ1 2 0.0063 0.0807 -0.0613 0.0283
27% in the treatment group. In Table 2.4, b0 = 1.3863 and b1 = −1 correspond to
pi(z = 0) = 0.8 and pi(z = 1) = 0.6, which mean that 20% of the population is cured
in the control group and 40% in the treatment group.
The simulation results show that estimates of b and β do not depend on the
assumption of the distribution. The bias of estimates based on the PH mixture cure
model are quite small. Even though the bias increase a little bit as the censoring rate
increases, the MSE of estimates get smaller as sample size increases from 200 to 500.
The same conclusion can be made even we increase cure rates from 12% to 20% in
the control group and 27% to 40% in the treatment group as shown in Table 2.4.
Investigate the effect of link functions
As discussed in the section of semiparametric PH mixture cure model, besides ‘logit’
link, ‘probit’ link and ‘cloglog’ can also be used to model the probability of cure.
Suppose we use the same input data that are generated in Table 2.3. We only
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consider sample size 500 and Weibull distribution for survival times. We re-estimate
the unknown parameters b by ‘logit’ link, ‘probit’ link and ‘cloglog’ link respectively.
Then, re-calculate the cure rates for control group and treatment group by different
link functions. The estimates of parameters b and cure rates based on 500 replicates
are summarized in Table 2.5.
Table 2.5 Estimated cure rates for different link functions (n=500)
PHMC Survival Censoring Parameter True Logit Probit Cloglog
Distribution Distribution Values
Weibull U(0.5,9) bˆ0 2 2.0169 1.1463 0.7159
bˆ1 = −1 -1 -1.017 -0.5203 -0.4352
Cure Rate
Control 0.12 0.117 0.206 0.129
Treatment 0.27 0.269 0.327 0.266
From Table 2.5, we can see that even though the point estimates of unknown
parameters b are different, the estimated cure rates by different link functions are
quite close.
In order to visually see the effects of different link functions, we plot the esti-
mated uncure rates by ’logit’ link, ’probit’ link and ’cloglog’ link versus a continuous
covariate, which takes values ranging from −2 to 2.
From the Figure 2.1 , we can see that the estimated cure rates from ‘logit’ link,
‘probit’ link and ‘cloglog’ are quite close if the input is the same.
2.6 Application
In this section, we use an example to illustrate the use of smcure package for the
semiparametric PH mixture cure model.
23
Figure 2.1 Plot of different link functions.
Eastern Cooperative Oncology Group (ECOG) Data
We fit the semiparametric PH mixture cure model to the melanoma data from the
ECOG phase III clinical trial E1684 [16], which was also illustrated by PSPMCM SAS
macro [8]. The aim of the E1684 clinical trial was to evaluate the high dose interferon
alpha-2b (IFN) regimen against the placebo as the postoperative adjuvant therapy.
After deleting missing data, a total number of 284 observations is used in the analysis.
Treatment (0=control,1=treatment), gender (0=male,1=female) and age (continuous
variable which is centered to the mean) are used in both the incidence and latency
parts. The response variable is relapse free survival in years. The semiparametric PH
mixture cure model can be fitted as following:
> pd <- smcure(Surv(FAILTIME,FAILCENS)~TRT+SEX+AGE,cureform=~TRT+SEX+AGE,
data=e1684,model="ph",nboot=500)
The output is:
> printsmcure(pd)
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Call:
smcure(formula = Surv(FAILTIME, FAILCENS) ~ TRT + SEX + AGE, cureform =
~TRT + SEX + AGE, data = e1684, model = "ph", nboot = 500, Var = TRUE)
Cure probability model:
Estimate Std.Error Z value Pr(>|Z|)
(Intercept) 1.36493298 0.28769252 4.7444159 2.091088e-06
TRT -0.58847727 0.30645148 -1.9202951 5.482064e-02
SEX -0.08696490 0.32905294 -0.2642885 7.915576e-01
AGE 0.02033857 0.01445227 1.4072922 1.593408e-01
Failure time distribution model:
Estimate Std.Error Z value Pr(>|Z|)
TRT -0.153595097 0.172120117 -0.8923716 0.3721938
SEX 0.099458470 0.190788176 0.5213031 0.6021556
AGE -0.007664013 0.006695195 -1.1447033 0.2523321
The standard errors of the estimated parameters are obtained based on 500 bootstrap
samples. If considering the male with the median centered age of 0.579, we can draw
the fitted survival curves by the treatment group using the following commands:
> predm=predictsmcure(pd,newX=cbind(c(1,0),c(0,0),c(0.579,0.579)),
newZ=cbind(c(1,0),c(0,0),c(0.579,0.579)),model="ph")
> plotpredictsmcure(predm,model="ph")
The fitted survival curves for the male with median centered age are shown in Figure
2.2. The upper solid line is the allogeneic treatment group and lower dashed line is
the autologous treatment group. The IFN treatment has higher survival probability
than the placebo group.
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Figure 2.2 Fitted survival curves for the male with median centered age.
Figure 2.3 Fitted survival curves for the female with median centered age.
> predf=predict.smcure(pd,newX=cbind(c(1,0),c(1,1),c(0.579,0.579)),
newZ=cbind(c(1,0),c(1,1),c(0.579,0.579)),model="ph")
> plotpredictsmcure(predf,model="ph")
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Similarly, we fitted the survival curves by the treatment group for the female at the
same age, which are shown in Figure 2.3. The upper solid line is the IFN treatment
and lower dashed line is the control group. The IFN treatment has higher survival
probability than the placebo group for female as well.
2.7 Conclusions
We develop an R package to estimate the semiparametric PH mixture cure model.
The cure probability part is estimated by the generalized linear model which allows
many link functions, such as logit, probit and cloglog. The latency part can
follow the PH model. The semiparametric estimation procedures are based on the
EM algorithm for both models. The smcure package in R is developed for imple-
menting the semiparametric estimation methods to the PH mixture cure model with
covariates.
2.8 Availability
The package smcure and the relevant documentation can be freely downloaded from
CRAN webpage http://cran.r-project.org/package=smcure.
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Chapter 3
New Program Development of Sample Size
Estimation for PH Mixture Cure Model
3.1 Abstract
Due to the advances in medical research, more and more diseases can be cured nowa-
days, which largely increases the need for an easy-to-use software in calculating sample
size of clinical trials with cure fractions. Current available sample size software, such
as PROC POWER in SAS, Survival Analysis module in PASS, powerSurvEpi pack-
age in R are all based on the standard proportional hazards (PH) model which is not
appropriate to design a clinical trial with cure fractions. Instead of the standard PH
model, the PH mixture cure model is an important tool in handling the survival data
with possible cure fractions. However, there are no tools available that can help deal
with the design of a trial with cure fractions. Therefore, we develop an R package
NPHMC to determine the sample size needed for such study design.
3.2 Introduction
Sample size calculation is an important component in designing randomized controlled
clinical trials with time-to-event endpoints. Assuming constant hazard ratio between
the treatment arm and control arm, the following sample size formula based on the
standard PH model has been widely used in practice[24, 25]:
n = (Zα/2 + Zθ)
2
p(1− p)β20P (δ = 1)
, (3.1)
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where α specifies the level of significance of the statistical test and 1 − θ specifies
the power of the statistical test; Zα/2 and Zθ are the upper α/2 and θ percentiles of
the standard normal distribution, respectively; p is the proportion of patients being
assigned to the treatment arm; β0 is the log-hazard ratio between treatments; δ is the
censoring indicator (1 for failure and 0 for censoring), and P (δ = 1) is the probability
of failure. Assuming SC(t) = P (C ≥ t) is the survival function of the censoring
time and f0(t) is the density function of survival times for uncured patients in the
control arm, P (δ = 1) =
∫∞
0 SC(t)f0(t)dt. Formula (3.1) has been implemented in
most software, and a common assumption is that the baseline density function f0(t)
follows the exponential distribution and the survival function of censoring time SC(t)
is uniform, such as PROC POWER in SAS.
One unstated assumption of the standard PH model is that all individuals under
study are susceptible to the adverse event of interest, and they would experience the
event eventually if there was no censoring. However, more and more patients will
be cured nowadays due to the advances in recent medical research, that is, those
patients may never experience the event even after a sufficient follow-up period. The
mixture cure model [17, 22, 26] is particularly designed to handle the dataset with a
cure fraction. Unlike the standard survival model, the mixture cure model has two
components in order to model the cure probability and the survival probability of
uncured patients.
Assume S∗j (·) denote the overall survival function, Sj(·) denote the survival func-
tion of uncured patients and pij (0 ≤ pij < 1) is the cure rate in arm j, j = 0 for
control arm and j = 1 for treatment arm. The mixture cure model can be written as
S∗j (t) = pij + (1− pij)Sj(t). (3.2)
Specifically, the PH mixture cure model is designed by assuming the PH model for
survival probability of uncured patients Sj(t) and logistic regression for the cure
probability pij.
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In this chapter, we design an R package NPHMC to implement the sample size
calculation proposed in [29]. The sample size formula based on the PH mixture cure
model (3.2) includes the sample size calculation based on the standard PH model.
Thus, the R package NPHMC is an extension of the exiting sample size software for
designing survival trial. In the next Section, we outline the computational method.
The R function and its arguments are described in Section 3.4. A simulation study
comparing parametric with nonparametric sample size calculation is discussed in
Section 3.5. Two examples are provided to illustrate the usage of the NPHMC package
in Section 3.6.
3.3 Computational Method
Let T denote the observed times, which is the minimum of the failure time and
censoring time. We assume that the censoring is independent. Let λ∗j(·) denote the
overall hazard function and λj(·) denote the hazard function of uncured patients for
arm j, j = 0, 1 respectively. The PH mixture cure model (3.2) assumes the constant
hazard ratio between the treatment arm and the control arm, that is
λ1(t) = eβ0λ0(t)
and the difference of the odds ratio of cure rates between two arms is a constant,
which can be written as logit(pi1) = logit(pi0) + γ0, where β0 and γ0 are unknown
parameters. When pi0 = pi1 = 0, it reduces to the standard PH model.
For a clinical trial with a proportion of patients being cured, we are interested in
testing
H0 : S1(t) = S0(t) and pi1 = pi0,
which is equivalent to
H0 : β0 = γ0 = 0
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. Based on the alternative hypotheses (Ha,n : β0 = βa/
√
n, γ0 = γa/
√
n) and the
log-rank test, Wang et al. [29] has shown that to achieve a power of 1− θ, the total
sample size for the PH mixture cure model can be determined by
n = (Zθ + Zα/2)
2 ∫∞
0 SC(t)f0(t)dt
p(1− p)β20(1− pi0)
{ ∫∞
0 m(γ0, β0, pi0)SC(t)f0(t)dt
}2 , (3.3)
where m(γ0, β0, pi0) = pi0{γ0/β0 +Λ0(t)}/S∗0(t)−1. When pi0 = 0, m(γ0, β0, pi0) = −1.
The above sample size formula is reduced to the standard PH model sample size
formula as given in (3.1).
Let τa denote the accrual period, τf denote the follow-up time and τ denote the
total study length with τ = τa + τf . Let g(t) denote the probability density function
of accrual times and three (uniform, increasing and decreasing) accrual patterns are
considered in the package. We also assume that the only censoring is due to adminis-
trative censoring at time τ , and there is no loss to follow-up or competing risks. The
probability density functions g(t) of accrual times and their corresponding survival
functions SC(t) of the censoring times for the uniform, increasing and decreasing
accruals are summarized in Table 3.1.
Table 3.1 Density functions g(t) of accrual times and the corresponding survival
functions SC(t) of censoring times.
Accrual g(t) SC(t)
Uniform g(t) =
{ 1
τa
if 0 < t ≤ τa
0 otherwise
SC(t) =

1 if t ≤ τf
τa+τf−t
τa
if τf < t ≤ τa + τf
0 if t > τa + τf
Increasing g(t) =

2t
τ2a
if 0 < t ≤ τa
0 otherwise
SC(t) =

1 if t ≤ τf
(τa+τf−t)2
τ2a
if τf < t ≤ τa + τf
0 if t > τa + τf
Decreasing g(t) =

2(τa−t)
τ2a
if 0 < t ≤ τa
0 otherwise
SC(t) =

1 if t ≤ τf
1− (τf−t)2
τ2a
if τf < t ≤ τa + τf
0 if t > τa + τf
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Examples Under Parametric Assumption
Uniform Accrual and Exponential Distribution
The uniform accrual assumes that patients enter a study at a constant rate 1/τa. The
exponential distribution with the rate of λ0 assumes that the patients in the control
arm has mean survival time of 1/λ0 and hazard risk in the control arm is changed by
a constant λ0, that is λ0(t) = λ0, Λ0(t) = λ0t and S0(t) = e−λ0t. Plugging the defined
survival functions SC(t) and other information into formula (3.3), the sample size is
calculated as
n =
(Zθ + Zα/2)2
(∫ τf
0 λ0e
−λ0tdt+
∫ τa+τf
τf
τa+τf−t
τa
λ0e
−λ0tdt
)
p(1− p)β20(1− pi0)
{∫ τf
0 m(γ0, β0, pi0)λ0e−λ0tdt+
∫ τa+τf
τf
τa+τf−t
τa
m(γ0, β0, pi0)λ0e−λ0tdt
}2 , (3.4)
where m(γ0, β0, pi0) = pi0(γ0/β0+λ0t)pi0+(1−pi0)e−λ0t − 1.
Increasing Accrual and Weibull Distribution
The increasing accrual assumes that patients enter a study with the density function
of g(t) = 2t
τ2a
. The Weibull distribution with scale parameter λ0 and shape parameter k
is assumed for survival times of uncured patients, which can be written as Comparing
to the exponential assumption, the Weibull distribution allows increasing hazard rate
(k > 1), constant hazard rate (k = 1) and decreasing hazard rate (0 < k < 1). The
sample size is calculated as
n =
(Zθ + Zα/2)2
(∫ τf
0 λ0(t)S0(t)dt+
∫ τa+τf
τf
(τa+τf−t)2
(τa)2 λ0(t)S0(t)dt
)
p(1− p)β20(1− pi0)
{∫ τf
0 m(γ0, β0, pi0)λ0(t)S0(t)dt+
∫ τa+τf
τf
(τa+τf−t)2
(τa)2 m(γ0, β0, pi0)λ0(t)S0(t)dt
}2 ,
(3.5)
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where m(γ0, β0, pi0) = pi0(γ0/β0+λ0t
k)
pi0+(1−pi0)e−λ0tk
− 1, λ0(t) = λ0k(λ0t)k−1, Λ0(t) = (λ0t)k and
S0(t) = e−(λ0t)
k .
Example Under Nonparametric Estimation of Parameters
(Sˆ0(t), pˆi0, γˆ0, βˆ0)
Let t(1) < t(2) < · · · < t(k) be the distinct failure times. If observed/historical data is
available, the survival function S0(t), cure rate pi0, log odds ratio γ0 and log hazard
ratio β0 can be estimated from the PH mixture cure model, which is implemented by
smcure package in R [4]. In this situation, only α, θ, p and accrual pattern need to
be specified. The sample size formula for nonparametric estimation is written as
n =
(Zθ + Zα/2)2
k∑
i=1
Sˆ0(t(i))SC(t(i))
p(1− p)β20(1− pi0)
{ k∑
i=1
Sˆ0(t(i))SC(t(i))mˆ(γ0, β0, pi0; t(i))
}2 , (3.6)
where mˆ(γ0, β0, pi0; ti) = pi0{γ0/β0 + Λˆ0(t)}/Sˆ∗0(t) − 1, Λˆ0(t) = log(−Sˆ0(t)), Sˆ∗0(t) =
pi0 + (1− pi0)Sˆ0(t).
3.4 Package Description
The sample size formula (3.3) under the exponential or the Weibull distribution with
different accrual patterns and formula (3.6) are implemented in the NPHMC package.
The NPHMC function in the package can be called with the following syntax:
NPHMC <- function(power, alpha, accrualtime, followuptime, p,
accrualdist=c("uniform","increasing","decreasing"), hazardratio,
oddsratio, pi0, survdist=c("exp","weib"), k, lambda0, data=NULL)
The arguments are:
33
• power: specifies the required power. The default power = 80%.
• alpha: specifies the level of significance of the statistical test. The default is 0.05.
• accrualtime: specifies the length of accrual period.
• followuptime: specifies the follow-up time.
• p: specifies the proportion of subjects in each arm. The default p = 0.5.
• accrualdist: specifies the accrual rate distribution. It can be "uniform",
"increasing" or "decreasing".
• hazardratio: specifies the hazard ratio of uncured patients between two arms, which
is equivalent to eβ0 = λ1(t)/λ0(t). The value must be greater than 0.
• oddsratio: specifies the odds ratio of cure rates between two arms, which is equiv-
alent to eγ0 = pi11−pi1 /
pi0
1−pi0 . The value should be greater than 0 if cure rates exist. It
can be 0 if there is no cure rate.
• pi0: specifies the cure rate for the control arm, which is between 0 and 1.
• survdist: specifies the survival distribution of uncured patients. It can be "exp" or
"weib".
• k: if survdist = "weib", the shape parameter k needs to be specified. By default
k = 1, which refers to the exponential distribution.
• lambda0: specifies the scale parameter of exponential distribution or Weibull distri-
bution for survival times of uncured patients in control arm.
The density function of Weibull distribution with shape parameter k and scale pa-
rameter λ0 is given by
f(t) = λ0k(λ0t)k−1 exp(−(λ0t)k), for t > 0
.
34
• data: if observed/historical data is available, the sample size can be calculated based
on the nonparametric estimators from the PH mixture cure model by smcure package
in R. The data must contain three columns with the order of "Time", "Status" and
"X" where "Time" refers to time to event of interest, "Status" refers to censoring
indicator (1 = event of interest happens, and 0 = censoring) and "X" refers to arm
indicator (1 = treatment and 0 = control). By default, data = NULL.
Output:
If data = NULL, the output will display
• PH Mixture Cure Model: n
• Standard PH Model: n
When data is specified, the output will first display the estimators from the
smcure package in R, and then show results from the NPHMC package.
• Estimators from smcure package
• PH Mixture Cure Model: n
• Standard PH Model: n
3.5 Simulation Study
In this section, we conduct a simulation study to investigate the performance of
the NPHMC package based on the PH mixture cure model. Two sets of results are
reported. One is based on the fully parametric approach, and the other is based on
the nonparametric approach.
The following settings are used in the simulation study: (1) an exponential dis-
tribution with parameter λ0 = 1, and a Weibull distribution with shape parameter
k = 2 and scale parameter λ0 = 1 are assumed for survival distributions of uncured
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patients; (2) an accrual period of 3 years and a follow-up time of 4 years; (3) an equal
allocation p = 0.5; (4) a number of 500 observations is generated in each dataset; (5)
simulation results are based on 200 replications.
Table 3.2 Comparison of Exponential Parametric Sample Size Estimation with
Nonparametric Sample Size Estimation (200 replications)
Accrual Parametric Nonparametric
pi0 pi1 OR λ0 λ1 HR k Rate Sample Size Sample Size
0.2 0.4 2.667 1 1/2 0.5 1 Uniform 110 111
Increasing 108 112
decreasing 112 112
0.45 3.273 Uniform 88 89
Increasing 87 90
decreasing 89 90
0.5 4.000 Uniform 73 74
Increasing 72 74
decreasing 73 74
0.2 0.5 4.000 1 1/2 0.5 1 Uniform 73 74
Increasing 72 74
decreasing 73 74
1/2.5 0.4 Uniform 59 60
Increasing 58 60
decreasing 59 60
1/3 0.3 Uniform 50 51
Increasing 49 51
decreasing 51 51
We first compare the parametric estimation approach based on the exponential
distribution with the nonparametric estimation approach in Table 3.2. We fix pi0 =
0.2, λ0 = 1, and then set pi1 = (0.4, 0.45, 0.5) and λ1 = (1/2, 1/2.5, 1/3) respectively,
which correspond to the values of oddsratio = (2.6667, 3.2727, 4) and hazardratio
= (0.5, 0.4, 0.3). In Table 3.3, we consider the Weibull distribution with k = 2. The
same settings of odds ratio and hazards ratio are used. Both tables show that the
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Table 3.3 Comparison of Weibull Parametric Sample Size Estimation with
Nonparametric Sample Size Estimation (200 replications)
Accrual Parametric Nonparametric
pi0 pi1 OR λ0 λ1 HR k Rate Sample Size Sample Size
0.2 0.4 2.667 1 0.707 0.5 2 Uniform 115 125
Increasing 115 124
decreasing 115 127
0.45 3.272 Uniform 92 96
Increasing 92 93
decreasing 92 97
0.5 4.000 Uniform 75 77
Increasing 75 76
decreasing 75 79
0.2 0.5 4.000 1 0.707 0.5 2 Uniform 75 77
Increasing 75 76
decreasing 75 79
0.632 0.4 Uniform 61 64
Increasing 61 61
decreasing 61 64
0.548 0.3 Uniform 48 50
Increasing 48 49
decreasing 48 50
results from the nonparametric sample size estimation are quite close to those based
on the parametric approach.
3.6 Examples
Parametric Sample Size Estimation
If the survival curve in each arm is assumed to follow exponential distribution or
Weibull distribution, besides the specifications of power, alpha, accrualtime, follow
uptime and p, the user needs to give accrualdist, survdist, k, lambda0, and as-
sumption of relationship between two arms, such as hazardratio and oddsratio in
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order to calculate sample size for the PH mixture cure model.
For example, a survival trial will follow a uniform accrual with an accrual period
of 3 years and a follow-up period of 4 years with equal amount of patients in each
arm (p = 0.5). The mean life of uncured patients in control arm will be 2 years and
the mean life of uncured patients in treatment arm will be 2.5 years. Assume both
arms follow the exponential distribution. Further, assume cure rates are pi0 = 0.1 and
pi1 = 0.2 for the control arm and treatment arm. At 5% significance level, to detect a
25% improvement in mean survival time from 2 to 2.5 years and achieve 90% power
of statistical test, the estimated sample size can be obtained by the following code:
> NPHMC(power=0.90,alpha=0.05,accrualtime=3,followuptime=4,p=0.5,
accrualdist="uniform",hazardratio=2/2.5,oddsratio=2.25,pi0=0.1,
survdist="exp",k=1,lambda0=0.5)
The output is:
========================================================================
SAMPLE SIZE CALCULATION FOR PH MIXTURE CURE MODEL AND STANDARD PH MODEL
========================================================================
PH Mixture Cure Model: n = 429
Standard PH Model: n = 908
A sample size of 429 patients will be needed to achieve a power of 90% based on
the PH mixture cure model. The sample size from the standard PH model is 908
which is overestimated if there exits a cure rate.
Nonparametric Sample Size Estimation When
Observed/Historical Data is Available
We illustrate the application of NPHMC package by melanoma data from the ECOG
phase III clinical trial e1684 [16]. The ECOG trial e1684 was a two-arm phase III
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clinical trial comparing high dose interferon alpha-2b with an observation arm. The
primary endpoint was relapse-free survival (RFS), with RFS defined as the time from
randomization until progression of the tumor or death. Note that our intention here
is not to re-design the trial but to show the application of the package.
If an observed/historical data is given, users only need to specify power, alpha,
accrualtime, followuptime, p, accrualdist and data. The hazard ratio and cure
rates can be directly estimated from the available data, therefore the sample size can
be obtained by the following code:
> NPHMC(power=0.80,alpha=0.05,accrualtime=4,followuptime=3,p=0.5,
accrualdist="uniform",data=e1684szdata)
The output is:
Call:
smcure(formula = Surv(Time, Status) ~ X, cureform = ~Z, data = data,
model = "ph", Var = FALSE)
Cure probability model:
Estimate
(Intercept) 1.2850677
Z -0.5455204
Failure time distribution model:
Estimate
X -0.1643542
========================================================================
SAMPLE SIZE CALCULATION FOR PH MIXTURE CURE MODEL AND STANDARD PH MODEL
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========================================================================
PH Mixture Cure Model with KM estimators: n = 454
Standard PH Model with KM estimators: n = 251
The package first fitted the data using the smcure R package with the treatment
as a covariate. The log hazard ratio is estimated as βˆ0 = -0.164. The coefficients of
logistic regression model for cure probability model are 1.285 and -0.5455, which lead
to cure rates for the observation arm and the interferon arm as pˆi0 = 1 − e1.2851+e1.285 =
0.2167 and pˆi1 = 1− e1.285−0.54551+e1.285−0.5455 = 0.3231. To achieve a power of 80%, a sample size
of 454 is required based on the estimates from the PH mixture cure model. A sample
size of 251 is calculated based on the standard PH model assumption, which will lead
to a underpowered trial if there is a cure fraction.
3.7 Conclusions
We develop an R package to estimate the sample size of the PH mixture cure model.
Comparing to existing software, the main advantage of this package is to allow a cure
fraction in survival trial. Besides that, this package can allow patients to enter study
with different patterns and also different hazard patterns for the uncured patients.
Therefore, the NPHMC package provides an important and flexible tool in sample size
design in survival trial with or without cure fractions.
3.8 Availability
The package NPHMC and the relevant documentation can be freely downloaded from
CRAN webpage http://cran.r-project.org/package=NPHMC.
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Chapter 4
New Estimation Method for Semiparametric PH
Mixture Cure Model with Competing Risks
Data
4.1 Introduction
Competing risks data are commonly seen in medical research particularly in survival
analysis when subjects are at risk of failure from K different causes. When one event
occurs, it precludes the occurrence of any other events. The PH mixture cure model
is commonly used regression model that accounts for the cure fraction. Considering
two types of failures k = 1, 2, within the mixture cure model framework, it is assumed
that an individual will fail from the event of interest or other risks. The following
flow chart can show you how cure fraction works in competing risks data framework.
Figure 4.1 Cure Model with Competing Risks Data.
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In Figure 4.1, it is obvious that cure fraction not only exits in censored patients but
also in those patients who died of other causes. Ignoring the competing risks would
lead the bias in estimating cure rates. In this project, I propose a new estimation
method for semiparametric PH mixture cure model with competing risks data. The
estimation is based on maximum likelihood of the full likelihood. In next sections, I
will discuss data and model, computational method, simulation study and real data
analysis for the semiparametric PH mixture cure model with competing risks data.
4.2 Data and Model
Let T1 be the failure time from the event of interest, T2 be the failure time from all
other risks, Ti be the event time where T = (T1 ∩ T2) and Ci be the right censoring
times for ith individual. εi ∈ (1, . . . , K) indicates the cause of failure. We consider
K = 2 in this study (ε = 1 for event of interest; ε = 2 for other causes). Let
T˜ = min(T,C) and δ = I(T ≤ C). z be a vector of covariates.
Let O = (T˜i, δi, δiεi, zi) denote the observed competing risks data for the ith
individual i = 1, · · · , n, where T˜i is the observed survival time, δi is the censoring
indicator with δi = 1 for the uncensored time and δi = 0 for the censored time, and zi
are the possible covariates that affect the cure probability, cause of death probability
and marginal survival probability for specific cause of death, respectively. We assume
that (Ti, εi) are independent of Ci given covariates.
Let Y be the indicator that an individual will eventually (Y = 1) or never (Y =0)
experience the event of interest, with the probability of pi(bz). Usually, a logit link
function
pi(bz) = exp(bz)1 + exp(bz) ,
where b is a vector of unknown parameters, is used to model the probability of being
uncure. The probability of being cured is 1− pi(bz).
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Let pi(θz) be the probability of failure from the event of interest and 1−pi(θz) be
the probability of failure from other risks. It is obvious that if an individual is cured
(Y = 0), then the individual must fail from other risks (ε = 2). Given an individual
is uncured (Y = 1), the conditional probability of failure from the event of interest
is assumed to have the following logistic form,
P (ε = 1|Y = 1) = exp(θz)1 + exp(θz) .
Therefore, the probability of failure from the jth cause is given by
P (ε = j) =

pi(bz)pi(θz) if j = 1
1− pi(bz) + pi(bz)[1− pi(θz)] if j = 2
where P (ε = 1) + P (ε = 2) = 1.
Let Sj(t; z) be the conditional survival function given that failure is due to the
jth cause. The survival function Sj(t; z) is given by
Sj(t; z) = P (Ti > t|εi = j) =

S0j(t)exp(βjz) if j = 1
S0j(t)exp(βjz) if j = 2
where S0j(t) is a cause-specific baseline survival function and βj is a vector of regres-
sion coefficients for jth cause.
4.3 Computational Method
Let Θ = (b,θ,β1,β2, S01(t), S02(t)) be the unknown parameters. The EM algorithm
is used to estimate the parameters of interest in the mixture cure model with com-
peting risks data. The estimation is based on the maximum likelihood method.
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Likelihood
On the basis of the observed data O = (T˜i, δi, δiεi, zi), the observed likelihood function
for the unknown parameters Θ under the PH mixture cure model is given by
Lo =
n∏
i=1
{pi(bzi)pi(θzi)h1(ti)S1(ti)}I(εi=1)δi
{[(1− pi(bzi)) + pi(bzi)(1− pi(θzi))]h2(ti)S2(ti)}I(εi=2)δi
{pi(bzi)pi(θzi)S1(ti) + [(1− pi(bzi)) + pi(bzi)(1− pi(θzi))]S2(ti))}1−δi
(4.1)
where pi(bzi) is probability of being uncured for ith individual, pi(θzi) is probability
of failing from event of interest for ith individual, S1(ti) is the survival function
from event of interest and S2(ti) is the survival function due to other causes for ith
individual. hj(·) is the hazard function corresponding to Sj(·) for jth type of risk,
j = 1, 2.
Given the cure indicator y = (y1, y2, · · · , yn) and the observed data O, the com-
plete likelihood function can be expressed as
Lc =
n∏
i=1
{pi(bzi)pi(θzi)h1(ti)S1(ti)}I(εi=1)δi
{[1− pi(bzi)]1−yi [pi(bzi)(1− pi(θzi))]yh2(ti)S2(ti)}I(εi=2)δi
{pi(bzi)pi(θzi)S1(ti)}I(εi=1)(1−δi)
{[1− pi(bzi)])1−yi [pi(bzi)(1− pi(θzi))]yiS2(ti))}I(εi=2)(1−δi)
(4.2)
The logarithm of the complete likelihood function can be written as
lc(b,θ,β1,β2; O,y) = lc1(b; O,y) + lc2(θ; O,y) + lc3(β1; O,y) + lc4(β2; O,y),
where
lc1(b) =
n∑
i=1
[I(εi = 1) + I(εi = 2)yi] log pi(bzi) +
n∑
i=1
I(εi = 2)(1− yi) log(1− pi(bzi))
(4.3)
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lc2(θ) =
n∑
i=1
I(εi = 1) log pi(θzi) +
n∑
i=1
I(εi = 2)yi log(1− pi(θzi)) (4.4)
lc3(β1, S01(t)) =
n∑
i=1
[I(εi = 1)δi log h1(ti) + I(εi = 1) logS1(ti) (4.5)
lc4(β2, S02(t)) =
n∑
i=1
[I(εi = 2)δi log h2(ti) + I(εi = 1) logS2(ti) (4.6)
with respect to the unknown parameters Θ(m) = (b(m),θ(m),β(m)1 ,β
(m)
2 , S01(t)(m), S02(t)(m)).
EM Algorithm
The E-step in the EM algorithm computes the conditional expectation of the complete
log-likelihood with respect to the three unobserved probabilities P (Y = 1, ε = 1),
P (Y = 1, ε = 2), and P (Y = 0, ε = 2). These three probabilities sum to 1 and can
be given by
P (Y = 1, ε = 1) = δI(ε = 1)
+ (1− δ) pi(b)pi(θ)S1(t)[1− pi(b)]S2(t) + pi(b)pi(θ)S1(t) + pi(b)[1− pi(θ)]S2(t)
(4.7)
P (Y = 1, ε = 2) = δI(ε = 2) pi(b)[1− pi(θ)]S2(t)[1− pi(b)]S2(t) + pi(b)[1− pi(θ)]S2(t)
+ (1− δ) pi(b)[1− pi(θ)]S2(t)[1− pi(b)]S2(t) + pi(b)pi(θ)S1(t) + pi(b)[1− pi(θ)]S2(t)
(4.8)
P (Y = 0, ε = 2) = δI(ε = 2) [1− pi(b)]S2(t)[1− pi(b)]S2(t) + pi(b)[1− pi(θ)]S2(t)
+ (1− δi) [1− pi(b)]S2(t)[1− pi(b)]S2(t) + pi(b)pi(θ)S1(t) + pi(b)[1− pi(θ)]S2(t)
(4.9)
45
Let pˆ(m)11,i = P (yi = 1, εi = 1|O,Θ(m)) and pˆ(m)ε,1i = P (εi = 1|O,Θ(m)), then
pˆ
(m)
ε,1i = pˆ
(m)
11,i. Let pˆ
(m)
12,i = P (yi = 1, εi = 2|O,Θ(m)) and pˆ(m)02,i = P (yi = 0, εi =
2|O,Θ(m)) and pˆ(m)ε,2i = P (εi = 2|O,Θ(m)), then pˆ(m)ε,2i = pˆ(m)12,i + pˆ(m)02,i. The expectations
of (4.3),(4.4),(4.5) and (4.6) can be written as
E(lc1) =
n∑
i=1
[pˆ(m)11,i + pˆ(m)12,i] log[pi(bzi)] + pˆ(m)02,i log[1− pi(bzi)]
, (4.10)
E(lc2) =
n∑
i=1
pˆ(m)11,i log[pi(θzi)] + pˆ(m)12,i log[1− pi(θzi)]
, (4.11)
E(lc3) =
n∑
i=1
δipˆ(m)ε,1i log h1(t;β1) + pˆ(m)ε,1i logS1(t;β1)
, (4.12)
E(lc4) =
n∑
i=1
δipˆ(m)ε,2i log h2(t;β2) + pˆ(m)ε,2i logS2(t;β2)
. (4.13)
The M-step in the EM algorithm is to maximize (4.10), (4.11), (4.12) and (4.13)
with respect to the unknown parameters Θ = (b,θ,β1,β2, S01(t), S02(t)). The pa-
rameters in equation (4.10) and equation (4.11) can be easily estimated by ‘optim’
function in R.
Peng and Dear [22] and Sy and Taylor [26] proposed a partial likelihood type
method to estimate β1 and β2 without specifying the baseline hazard functions. The
estimating equation (4.12) and (4.13) can be rewritten as
log
n∏
i=1
[h0(ti) exp(βzi + log(p(m)ε,ji ))]δiS0(ti)exp(βzi+log(p
(m)
ε,ji)) (4.14)
which is similar to the log-likelihood function of the standard PH model with the
additional offset variable log(p(m)ε,ji ), j = 1, 2. Therefore, the parameters in equation
(4.12) and (4.13) can be estimated by ‘coxph’ package in R. A detailed presentation
can be found in Peng [20], Peng and Dear [22], and Sy and Taylor [26].
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Estimation of Baseline Survival Function
In order to proceed the E-step in the EM algorithm, we need to update the estimated
survival function S1(t) and S2(t) at each iteration. Let t(j1) < t(j2) < · · · < t(jk) be
the distinct uncensored failure times due to the jth cause (j=1, 2), dt(jk) denote the
number of failures due to cause j at time t(jk) and R(t(jk)) denote the risk set at time
t(jk). The nonparametric Breslow-type estimator for baseline survival function S0j(t)
is given by
Sˆ0j(t) = exp
− ∑
k:t(jk)≤t
dt(jk)∑
i∈R(t(jk)) p
(m)
ε,jie
βzi
 . (4.15)
4.4 Simulation
In this section, we consider the sample sizes of n = 200, n = 500 and n = 800
respectively. Two distinct causes of failure is assumed in this study. The covariate z is
a binary variable, which is generated independently from the binary distribution with
probability of 0.5. We assume b = (2,−1), θ = (−1, 0.5), β1 = −0.5 and β2 = −1.
The cure indicator Y is generated from the binary distribution with probability of
pi(bz). The censoring time is generated from a uniform distribution U(c1, c2), where c1
and c2 are some constants to obtain the desired censoring rate. If the ith failure time
is greater than the ith censoring time, it is taken to be censored at this censoring time.
In the simulation, we consider two different sets of values for c1 and c2 so that different
censoring scenarios can be investigated. The survival times of uncure patients are
generated from a Weibull distribution where Sj(t) = exp[−(λjt)k exp(βjz)], j = 1, 2
(λ1 = 0.5, λ2 = 1 and k = 1) and a Lognormal distribution log N(0,1). The results
for different censoring scenarios are presented in Table 3.2. For each simulation set,
we generated 500 independent samples.
Tables 4.1 and 4.2 present the estimated biases and MSE from the PH mixture
cure model of six regression parameters b0, b1, θ0, θ1, β0 and β1 based on the logistic-
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Weibull data and logistic-lognormal data.
Table 4.1 Estimates of parameters from Logistic-Weibull PH mixture cure model
Average Parameter True Cure n = 200 n = 500 n = 800
censoring value rate Bias MSE Bias MSE Bias MSE
20.1 b0 2 0.12 0.0243 0.1018 -0.0177 0.0346 -0.0212 0.0247
b1 -1 0.27 -0.0454 0.1430 -0.0396 0.0572 -0.0317 0.0388
θ0 -1 0.0089 0.0687 0.0086 0.0268 0.0063 0.0155
θ1 0.5 0.0847 0.1529 0.02132 0.0649 0.0196 0.0345
β0 -0.5 -0.0940 0.1681 -0.0365 0.0547 -0.0173 0.0301
β1 -1 0.0192 0.0485 0.0017 0.0162 0.0002 0.0104
33.5 b0 1.3863 0.2 -0.5056 0.3281 -0.3758 1.7970 -0.5035 0.2956
b1 -1 0.4 -0.1124 0.1443 -0.1452 0.5357 -0.0689 0.0449
θ0 -1 0.2131 0.1136 0.2377 0.0820 0.2474 0.0773
θ1 0.5 0.2881 0.2347 0.2713 0.1393 0.2946 0.1257
β0 -0.5 0.0734 0.0630 0.0619 0.0275 0.0530 0.0160
β1 -1 -0.0169 0.0603 -0.0021 0.0220 0.0008 0.0151
Table 4.2 Estimates of parameters from Logistic-Lognormal PH mixture cure
model
Average Parameter True Cure n = 200 n = 500 n = 800
censoring value rate Bias MSE Bias MSE Bias MSE
23.3 b0 2 0.12 0.0725 0.1092 0.0516 0.0421 0.0318 0.0225
b1 -1 0.27 -0.3256 0.2527 -0.3306 0.1633 -0.3299 0.1425
θ0 -1 -0.0420 0.0815 -0.0396 0.0329 -0.0543 0.0202
θ1 0.5 0.1084 0.1704 0.0330 0.0904 0.0317 0.0467
β0 -0.5 0.0247 0.2020 0.0707 0.0751 0.0981 0.0481
β1 -1 -0.0065 0.0497 -0.0086 0.0171 -0.0254 0.0112
34.5 b0 1.3863 0.2 0.0096 0.0603 -0.0007 0.0259 -0.0137 0.0164
b1 -1 0.4 -0.2241 0.1576 -0.2313 0.0953 -0.2321 0.0784
θ0 -1 -0.1129 0.1053 0.1086 0.0474 -0.1185 0.0383
θ1 0.5 0.0507 0.2801 -0.0537 0.0955 -0.0501 0.0629
β0 -0.5 0.0674 0.3821 0.1498 0.1418 0.1646 0.0813
β1 -1 -0.0085 0.0606 -0.0165 0.0217 0.0252 0.0122
The simulation results show that point estimates do not depend on the assumption
of the distribution. The bias of estimates based on PH mixture cure model are
quite small on both Weibull distribution and lognormal distribution. The MSE of
estimates get smaller as sample size increases. The same conclusion can be made
when we increase cure rates from 12% to 20% in control group and 27% to 40% in
treatment group.
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4.5 Example
To illustrate the proposed estimation method for semiparametric PH mixture cure
model with competing risks data, we will consider the prostate cancer clinical trial
data. The survival times of 502 patients with prostate cancer entered the trial during
1967 to 1969 and were randomly allocated to different levels of treatment with the
drug diethylstilbestrol (DES). These data have been analyzed and published by many
authors [3, 14, 7]. Patients with missing covariates were excluded from this analysis.
There were 483 patients with completion information on covariates.
In this analysis, we consider two types of failures: (1) death due to prostate cancer
(2) death due to other causes. There were 125 patients who died from prostate cancer,
and 219 patients who died from other causes. The remaining 139 survival times were
censored. The censoring rate is 28.78%. Only covariate of drug treatment (0.0 or
0.2 mg coded as 0; 1.0 or 5.0 mg coded as 1) was considered in the analysis. The
proposed semiparametric mixture cure model approach is adopted and the result is
presented in Table 4.3.
Table 4.3 Maximum likelihood estimates for prostate cancer clinical trial data
based on semiparametric mixture cure model
Incidence Part Latency Part
Coefficient Cure incidence Cause of prostate cancer Prostate cancer Other causes
Constant 1.2713* (0.07) -0.1943 (0.12)
Treatment -0.9129* (0.23) -0.3011 (0.29) 0.0558 (0.23) -0.6318* (0.24)
* p-value < 0.05
The data were fitted by PH mixture cure model based on completing risks data
framework. The parameter b were estimated as b = (1.2713,−0.9129) which lead
to cure rates for the drug treatment group (0.0 or 0.2 mg) and the drug treatment
group (1.0 or 5.0 mg) as e1.27131+e1.2713 = 21.9% and
e1.2713−0.9129
1+e1.2713−0.9129 = 41.1%. Based on the
results, we can conclude that treatment had significant effect on estimating cure rate
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by logistic regression with p-value < 0.05. Treatment also had significant effect on
estimating failure times due to other causes.
4.6 Conclusions and Discussion
We proposed an EM based algorithm for estimating PH mixture cure model with
competing risks data. The estimation is based on maximum likelihood of the full
likelihood, and estimation process allows the nonparametric maximum likelihood es-
timates of the baseline survival functions to be used in the estimation of the param-
eters.
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Chapter 5
An Extension to Semiparametric AFT Mixture
Cure Model and Its Application in R
Another important statistical model in medical research is the AFT model. If the
AFT model is used to model the survival of uncure individuals, the cure model
is called the AFT mixture cure model. In this Chapter, I will first introduce the
standard AFT model and AFT mixture cure model, and then discuss the application
of AFT mixture cure model in R.
5.1 Semiparametric AFT Mixture Cure Model
As mentioned before, the latency part of mixture cure model can be specified by
either the PH model or the AFT model. The AFT model is specified as
log(T ) = βx + ε
where the distribution of the error term ε is unknown. The survival function can be
written as
S(t|x) = S0(teβx).
The mixture cure model is called the AFT mixture cure model if the assumption of
latency part follows AFT model. This section will focus on an estimation method for
the semiparametric AFT mixture cure model.
Let f(·) be the density probability function of ε and S(·) be the corresponding
survival function. The conditional survival function of T , given that the patient is
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not cured, is S(log(t) − βx). Assuming the censoring is independent and noninfor-
mative, the contribution to the likelihood from the ith uncensored patient (δi = 1) is
pi(zi)f(log(ti) − βx)/ti and 1 − pi(zi) + pi(zi)S(log(ti) − βxi) from censored patient
(δi = 0).
Similar to the semiparametric PH mixture cure model, we define yi as an indicator
of cure status of the ith patient, namely, yi = 1 if the patient is uncured and 0
otherwise, i = 1, 2, · · · , n.. Given y = (y1, y2, · · · , yn) and O, the complete data are
available, The logarithm of the complete likelihood function can be written as
lc(b,β; O,y) = lc1(b; O,y) + lc2(β; O,y), where
lc1(b; O,y) =
n∑
i=1
yi log[pi(zi)] + (1− yi) log[1− pi(zi)], (5.1)
lc2(β; O,y) =
n∑
i=1
yiδi log[h(log(ti)− βxi),xi)] + yi log[S(log(ti)− βxi)]. (5.2)
and h(·) = f(·)/S(·) is the hazard function of ε. We can see that (5.1) and (5.2)
are linear functions of latent variable Y . Therefore, we consider EM algorithm to
estimate the unknown parameter b and β.
The E-step in the EM algorithm computes the conditional expectation of the com-
plete log-likelihood with respect to y′is, given the observed data O and current esti-
mates of parameters Θ(m) = (b(m),β(m), S(m)0 (t)). The expectation of E(yi|O,Θ(m))
can be written as
w
(m)
i = E(yi|O,Θ(m)) = δi + (1− δi)
pi(zi)S(log(ti)− βxi)
1− pi(zi) + pi(zi)S(log(ti)− βxi)
∣∣∣∣∣
(O,Θ(m))
.(5.3)
Therefore, the estimation equations can be written as
E(lc1) =
n∑
i=1
w
(m)
i log[pi(zi)] + (1− w(m)i ) log[1− pi(zi)], (5.4)
E(lc2) =
n∑
i=1
δi log[w(m)i h(log(ti)− βxi)] + w(m)i log[S(log(ti)− βxi)]. (5.5)
The M-step in the EM algorithm is to maximize (2.6) and (2.7) with respect to
the unknown parameters. Similar to the PH mixture cure model, the parameters in
equation (5.4) can be easily estimated by ‘glm’ package in R.
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Zhang and Peng [31] proposed a rank-based estimation method to estimate β
in the M-step for the semiparametric AFT mixture cure model. They turned the
estimation equation (5.5) into a log-likelihood function of a standard semiparametric
AFT model, except for the constant term w(m)i , which is
log
n∏
i=1
[w(m)i h(log(ti)− βxi)]δi [S(log(ti)− βxi)w
(m)
i ].
This enables us to estimate β in the M-step by the existing semiparametric estima-
tion method for the AFT model [19]. Zhang and Peng [31] suggested to obtain the
estimator by maximizing the convex function G(β), where
G(β) = n−1
n∑
i=1
n∑
j=1
δiwj|εi − εj|I(εi − εj). (5.6)
Therefore, maximization of (5.5) can be realized by maximizing (5.6) through the
linear programming method in R.
Estimation of the Survival Function in the E-Step
Let τ1 < τ2 < · · · < τk be the distinct uncensored failure residuals, which is log ti−βxi,
i = 1, · · · , n, dτj denote the number of failures and R(τj) denote the risk set at τj.
An estimator of S0(ε|Y = 1) is given by
Sˆ0(ε|Y = 1) = exp
− ∑
j:τj<ε
dτj∑
i∈R(τj)w
(m)
i
 . (5.7)
Same as the semiparametric PH mixture cure model, we set Sˆ0(ε|Y = 1) = 0 for
ε > τk. Then Sˆ(t|Y = 1) = Sˆ0(ε|Y = 1).
Variance Estimation
Because of the complexity of the estimating equation in the EM algorithm, the second
derivative of estimation equation is not available. The same bootstrap method as the
PH mixture cure model is used to estimate the variance of AFT mixture cure model.
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5.2 Simulation Study
In the simulation study, the probability of cure is generated from a logistic model
where pi(z) = exp(bz)1+exp(bz) . The covariate z is fixed by design and is binary. Censoring
times are generated from a uniform distribution U(c1, c2), where c1 and c2 are some
constants. The results below are based on n = 200 and n = 500 respectively with
500 replications.
Table 5.1 Estimates from Logistic-Extreme AFTMC model (2,-1,0,2)
Censoring Censoring Parameter True n = 200 n = 500
Distribution Rate Values Bias MSE Bias MSE
U(0.5,30) 28.8 bˆ0 2 0.0305 0.1090 0.0252 0.0454
bˆ1 -1 0.0657 0.3608 0.0211 0.1095
βˆ0 0 -0.6916 0.5272 -0.6904 0.5280
βˆ1 2 0.0057 0.0711 0.0142 0.0313
U(0.5,9) 42.8 bˆ0 2 0.0720 0.3389 0.0355 0.0569
bˆ1 -1 -0.0801 1.1891 -0.1434 0.4802
βˆ0 0 -0.6680 0.5588 -0.6647 0.5360
βˆ1 2 -0.1093 0.2394 -0.0990 0.1054
U(0.5,5) 50.8 bˆ0 2 0.1496 1.1778 0.0088 0.1745
bˆ1 -1 -0.8977 2.4754 -0.7173 0.9915
βˆ0 0 -0.5143 0.3816 -0.5584 0.3956
βˆ0 2 -0.4277 0.4993 0.0982 0.0328
In Table 5.1, b0 = 2 and b1 = −1 correspond to pi(z = 0) = 0.88 and pi(z =
1) = 0.73 which mean that 12% of the population is cured in control group and
27% in treatment group. Table 5.1 presents the estimated biases and MSE from
the AFT mixture cure model of three regression parameters b0, b1 and β based on
logistic-Extreme data. The error distribution follows extreme distribution. The bias
are quite small with censoring rates change from light censoring (20%), moderate
censoring (40%), to heavy censoring (50%). Same as the PH mixture cure model, the
MSE get small when the sample size increase from 200 to 500.
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5.3 Application
To illustrate the usage of smcure R package for semiparametric AFT mixture cure
model, we fit the bone marrow transplant study for the refractory acute lymphoblastic
leukemia patients as an example. The semiparametric AFT mixture cure model can
be fitted as following:
> bmtfit <- smcure(Surv(Time,Status)~TRT,cureform=~TRT,
data=bmt,model="aft",nboot=200)
The output is:
> printsmcure(bmtfit)
Call:
smcure(formula = Surv(Time, Status) ~ TRT, cureform = ~TRT,
data = bmt, model = "aft", nboot = 200)
Cure probability model:
Estimate Std.Error Z value Pr(>|Z|)
(Intercept) 1.007354 0.2261408 4.4545448 8.407136e-06
TRT 0.427327 0.4843662 0.8822394 3.776474e-01
Failure time distribution model:
Estimate Std.Error Z value Pr(>|Z|)
(Intercept) 0.2101563 0.1783968 1.178027 0.2387859
TRT -0.3531250 0.2705977 -1.304982 0.1918991
The standard errors of estimated parameters are obtained based on 200 bootstrap
samples. The cure rate can be calculated based on the results from Cure probability
model part. For example, the cure rate for the autologous transplant is 19.2 percent,
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which is calculated by 1 − pˆi(z) = 1 − e1.007354+0.427327/(1 + e1.007354+0.427327). The
estimated survival curves with respect to the treatment can be obtained by
> predbmt=predictsmcure(bmtfit,newX=c(0,1),newZ=c(0,1),model="aft")
> plotpredictsmcure(predbmt,model="aft")
From the fitted survival curves in Figure 5.1, we can see that the patients from
the allogeneic treatment group has better survival probability than those from the
autologous treatment group.
Figure 5.1 Predicted Survival curves by treatment groups for bone marrow
transplant study. The upper solid line is the allogeneic treatment group and lower
dashed line is the autologous treatment group.
5.4 Conclusions
We develop an R package to estimate the semiparametric PH mixture cure and AFT
mixture cure models. The cure probability part is estimated by the generalized linear
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model which allows many link functions, such as logit, probit and cloglog. The
latency part can follow either the PH model or the AFT model. The semiparametric
estimation procedures are based on the EM algorithm for both models. This package
is an extension of the S-PLUS package semicure by Y. Peng which is for the PH
mixture cure model only, and the SAS macro PSPMCM [8] which accounts for the
PH mixture cure model and the parametric approach for the AFT mixture cure
model. The smcure package in R is developed for implementing the semiparametric
estimation methods to both the PH mixture cure model and the AFT mixture cure
model.
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Chapter 6
Summary and Conclusions
This dissertation is about advanced methodology development in mixture cure mod-
els. It consists of three projects: (1) Software Development for Estimating Semipara-
metric Mixture Cure Models (2) New Program of Sample Size Estimation with Cure
Fraction in R (3) New Estimation Method for Semiparametric Mixture Cure Model
with Competing Risks Data.
Modern medical treatments have substantially improved cure rates for many
chronic diseases and have generated increasing interest in appropriate statistical mod-
els to handle survival data with non-negligible cure fractions. The mixture cure model
is designed to model such data, which assumes that studied population is a mixture
of individuals who are cured and individuals who are not cured. The mixture cure
model assumes that a fraction of the survivors are cured from the disease of interest.
The failure time distribution for the uncured individuals (latency) can be modeled
by either parametric models or a semi-parametric proportional hazards model. A
straightforward way to identify whether a particular dataset might have a proportion
of long-term survivors is to look at the estimated survival curve. If the Kaplan-Meier
survival curve has a plateau at the end of the study, a cure model may be an appro-
priate and useful way to analyze the data. Some statistical research has been done
on mixture cure models, but none of the proposed statistical approaches has software
available for public use.
In this dissertation, I first develop an R package named smcure to estimate the
semiparametric proportional hazards (PH) mixture cure model and accelerated failure
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time (AFT) mixture cure model. The cure probability part is estimated by the
generalized linear model which allows many link functions, such as logit, probit
and cloglog. The latency part can follow either the PH model or the AFT model.
The semiparametric estimation procedures are based on the EM algorithm for both
models. This package is an extension of the S-PLUS package semicure by Y. Peng
which is for the PHMC model only, and the SAS macro PSPMCM [8] which accounts
for the PHMC model and the parametric approach for the AFTMC model.
Second, I develop another R package named NPHMC to estimate the sample size
based on the PH mixture cure model if cure fraction exits or standard PH model if
there is no cure. The package provides an important and flexible tool in sample size
design in survival trial with or without cure fractions.
Competing risks data are commonly seen in medical research particularly in sur-
vival analysis. I propose a new estimation approach based on the PH mixture cure
model in competing risks data framework. The estimation can be obtained from the
EM algorithm.
The mixture cure model generally requires a sufficiently long follow-up and large
sample sizes to identify the parameters in cure fraction and latent survival distribution
for uncured individuals (Farewell, 1986) [9]. Cautious interpretation of the cure
fraction estimate is needed when these is no evidence of sufficient follow-up and
enough samples. Therefore, it is recommended to use the mixture cure models in
situations where it is clear that a cured fraction exists and follow-up beyond the time
when most events have occurred.
Work in the future may include methodology developments and possible applica-
tion of cure models in real world. I will continue to maintain the two contributed
packages and add more features in the programs (such as different variance estima-
tion methods, goodness of fit, etc.) and complete simulation studies for competing
risks data. Besides the application in oncology, it would be interesting to apply cure
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models in other fields such as Alzheimer’s disease in Neurology where failure rates are
low, vaccine effectiveness, prophylactic treatments for pertussis, rabies, occupational
exposures in public health and procedural interventions with adjunctive treatments
in cardiovascular disease.
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Appendix A
Source Codes for smcure package
library(survival)
smrank <- function(beta,Time,X,n,w,Status){
error <- drop(log(Time)-beta%*%t(X))
tp <- numeric()
for(i in 1:n){
tp[i] <- sum(as.numeric((error[i]-error)<0)*abs(error[i]-error)*w*Status[i])
}
sum(tp)/n
}
smsurv <- function(Time,Status,X,beta,w,model){
death_point <- sort(unique(subset(Time, Status==1)))
if(model==’ph’) coxexp <- exp((beta)%*%t(X[,-1]))
lambda <- numeric()
event <- numeric()
for(i in 1: length(death_point)){
event[i] <- sum(Status*as.numeric(Time==death_point[i]))
if(model==’ph’)
temp <- sum(as.numeric(Time>=death_point[i])*w*drop(coxexp))
if(model==’aft’)
temp <- sum(as.numeric(Time>=death_point[i])*w)
temp1 <- event[i]
lambda[i] <- temp1/temp
}
HHazard <- numeric()
for(i in 1:length(Time)){
HHazard[i] <- sum(as.numeric(Time[i]>=death_point)*lambda)
if(Time[i]>max(death_point))HHazard[i] <- Inf
if(Time[i]<min(death_point))HHazard[i] <- 0
}
survival <- exp(-HHazard)
list(survival=survival)
}
em <- function(Time,Status,X,Z,offsetvar,b,beta,model,link,emmax,eps)
{
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w <- Status
n <- length(Status)
if(model == "ph") s <- smsurv(Time,Status,X,beta,w,model)$survival
if(model == "aft"){
if(!is.null(offsetvar)) Time <- Time/exp(offsetvar)
error <- drop(log(Time)-beta%*%t(X))
s <- smsurv(error,Status,X,beta,w,model)$survival
}
convergence<- 1000;i <-1
while (convergence > eps & i < emmax){
uncureprob <- matrix(exp((b)%*%t(Z))/(1+exp((b)%*%t(Z))),ncol=1)
if(model == "ph"){
survival<-drop(s^(exp((beta)%*%t(X[,-1]))))}
if(model == "aft"){
error <- drop(log(Time)-beta%*%t(X))
survival <- s}
## E step
w <- Status+(1-Status)*(uncureprob*survival)/((1-uncureprob)+uncureprob*survival)
## M step
logistfit<- eval(parse(text = paste("glm", "(", "w~Z[,-1]",",
family = quasibinomial(link=’", link, "’",")",")",sep = "")))
update_cureb <- logistfit$coef
if(!is.null(offsetvar))
update_cureb <- as.numeric(eval(parse(text =
paste("glm", "(", "w~Z[,-1]+offset(offsetvar)",",
family = quasibinomial(link=’", link, "’",")",")",sep = "")))$coef)
if(model == "ph") {
update_beta <- coxph(Surv(Time, Status)~X[,-1]+
offset(log(w)), subset=w!=0, method="breslow")$coef
if(!is.null(offsetvar)) update_beta <- coxph(Surv(Time, Status)~X[,-1]+
offset(offsetvar+log(w)), subset=w!=0, method="breslow")$coef
update_s <-smsurv(Time,Status,X,beta,w,model)$survival}
if(model == "aft") {
update_beta <- optim(rep(0,ncol(X)), smrank,
Time=Time,X=X,n=n,w=w,Status=Status,method="Nelder-Mead",
control=list(reltol=0.0001,maxit=500))$par
update_s <- smsurv(error,Status,X,beta,w,model)$survival}
convergence<-sum(c(update_cureb-b,update_beta-beta)^2)+sum((s-update_s)^2)
b <- update_cureb
beta <- update_beta
s<-update_s
uncureprob <- matrix(exp((b)%*%t(Z))/(1+exp((b)%*%t(Z))),ncol=1)
i <- i+1
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}
em <- list(logistfit=logistfit,b=b, latencyfit= beta,Survival=s,
Uncureprob=uncureprob,tau=convergence)
}
#####################
## main function ##
#####################
smcure <- function(formula,cureform,offset=NULL,data,na.action=na.omit,
model= c("aft", "ph"),link="logit", Var=TRUE,emmax=50,eps=1e-7,nboot=100)
{
call <- match.call()
model <- match.arg(model)
cat("Program is running..be patient...")
## prepare data
data <- na.action(data)
n <- dim(data)[1]
mf <- model.frame(formula,data)
cvars <- all.vars(cureform)
Z <- as.matrix(cbind(rep(1,n),data[,cvars]))
colnames(Z) <- c("(Intercept)",cvars)
if(!is.null(offset)) {
offsetvar <- all.vars(offset)
offsetvar<-data[,offsetvar]}
else offsetvar <- NULL
Y <- model.extract(mf,"response")
X <- model.matrix(attr(mf,"terms"), mf)
if (!inherits(Y, "Surv")) stop("Response must be a survival object")
Time <- Y[,1]
Status <- Y[,2]
bnm <- colnames(Z)
nb <- ncol(Z)
if(model == "ph") {
betanm <- colnames(X)[-1]
nbeta <- ncol(X)-1}
if(model == "aft"){
betanm <- colnames(X)
nbeta <- ncol(X)}
## initial value
w <- Status
b <- eval(parse(text = paste("glm", "(", "w~Z[,-1]",",
family = quasibinomial(link=’", link, "’",")",")",sep = "")))$coef
if(model=="ph") beta <- coxph(Surv(Time, Status)~X[,-1]+
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offset(log(w)), subset=w!=0, method="breslow")$coef
if(model=="aft") beta <- survreg(Surv(Time,Status)~X[,-1])$coef
## do EM algo
emfit <- em(Time,Status,X,Z,offsetvar,b,beta,model,link,emmax,eps)
b <- emfit$b
beta <- emfit$latencyfit
s <- emfit$Survival
logistfit <- emfit$logistfit
if(Var){
if(model=="ph") {b_boot<-matrix(rep(0,nboot*nb), nrow=nboot)
beta_boot<-matrix(rep(0,nboot*(nbeta)), nrow=nboot)
iter <- matrix(rep(0,nboot),ncol=1)}
if(model=="aft") {b_boot<-matrix(rep(0,nboot*nb), nrow=nboot)
beta_boot<-matrix(rep(0,nboot*(nbeta)), nrow=nboot)}
tempdata <- cbind(Time,Status,X,Z)
data1<-subset(tempdata,Status==1);data0<-subset(tempdata,Status==0)
n1<-nrow(data1);n0<-nrow(data0)
i<-1
while (i<=nboot){
id1<-sample(1:n1,n1,replace=TRUE);id0<-sample(1:n0,n0,replace=TRUE)
bootdata<-rbind(data1[id1,],data0[id0,])
bootZ <- bootdata[,bnm]
if(model=="ph") bootX <- as.matrix(cbind(rep(1,n),bootdata[,betanm]))
if(model=="aft") bootX <- bootdata[,betanm]
bootfit <- em(bootdata[,1],bootdata[,2],bootX,bootZ,offsetvar,b,beta,model,link,emmax,eps)
b_boot[i,] <- bootfit$b
beta_boot[i,] <- bootfit$latencyfit
if (bootfit$tau<eps) i<-i+1}
b_var <- apply(b_boot, 2, var)
beta_var <- apply(beta_boot, 2, var)
b_sd <- sqrt(b_var)
beta_sd <- sqrt(beta_var)
}
fit<-list()
class(fit) <- c("smcure")
fit$logistfit <- logistfit
fit$b <- b
fit$beta <- beta
if(Var){
fit$b_var <- b_var
fit$b_sd <- b_sd
fit$b_zvalue <- fit$b/b_sd
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fit$b_pvalue <- (1-pnorm(abs(fit$b_zvalue)))*2
fit$beta_var <- beta_var
fit$beta_sd <- beta_sd
fit$beta_zvalue <- fit$beta/beta_sd
fit$beta_pvalue <- (1-pnorm(abs(fit$beta_zvalue)))*2 }
cat(" done.\n")
fit$call <- call
fit$bnm <- bnm
fit$betanm <- betanm
fit$s <- s
fit$Time <- Time
if(model=="aft"){
error <- drop(log(Time)-beta%*%t(X))
fit$error <- error}
fit
printsmcure(fit,Var)
}
coefsmcure <- function(x, ...)
{
coef <- c(x$b,x$beta)
names(coef) <- c(x$bnm,x$betanm)
coef
}
printsmcure <- function(x,Var=TRUE, ...)
{
if(is.null(Var)) Var=TRUE
if(!is.null(cl <- x$call)) {
cat("Call:\n")
dput(cl)
}
cat("\nCure probability model:\n")
if (Var) {
b <- array(x$b,c(length(x$b),4))
rownames(b) <- x$bnm
colnames(b) <- c("Estimate","Std.Error","Z value","Pr(>|Z|)")
b[,2] <- x$b_sd
b[,3] <- x$b_zvalue
b[,4] <- x$b_pvalue}
if (!Var) {
b <- array(x$b,c(length(x$b),1))
rownames(b) <- x$bnm
colnames(b) <- "Estimate"
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}
print(b)
cat("\n")
cat("\nFailure time distribution model:\n")
if (Var) {
beta <- array(x$beta,c(length(x$beta),4))
rownames(beta) <- x$betanm
colnames(beta) <- c("Estimate","Std.Error","Z value","Pr(>|Z|)")
beta[,2] <- x$beta_sd
beta[,3] <- x$beta_zvalue
beta[,4] <- x$beta_pvalue}
if (!Var) {
beta <- array(x$beta,c(length(x$beta),1))
rownames(beta) <- x$betanm
colnames(beta) <- "Estimate"
}
print(beta)
invisible(x)
}
predictsmcure <- function(object, newX, newZ,model=c("ph","aft"), ...)
{
call <- match.call()
if(!inherits(object, "smcure")) stop("Object must be results of smcure")
if(is.vector(newZ)) newZ=as.matrix(newZ)
newZ=cbind(1,newZ)
if(is.vector(newX)) newX=as.matrix(newX)
s0=as.matrix(object$s,ncol=1)
n=nrow(s0)
uncureprob=exp(object$b%*%t(newZ))/(1+exp(object$b%*%t(newZ)))
scure=array(0,dim=c(n,nrow(newX)))
t=array(0,dim=c(n,nrow(newX)))
spop=array(0,dim=c(n,nrow(newX)))
if(model==’ph’)
{ebetaX=exp(object$beta%*%t(newX))
for( i in 1:nrow(newZ))
{scure[,i]=s0^ebetaX[i]}
for (i in 1:n){
for (j in 1:nrow(newX)){
spop[i,j]=uncureprob[j]*scure[i,j]+(1-uncureprob[j])
}
}
prd=cbind(spop,Time=object$Time)
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}
if(model==’aft’)
{
newX=cbind(1,newX)
ebetaX=exp(object$beta%*%t(newX))
for( i in 1:nrow(newX))
{t[,i]=ebetaX[i]*exp(object$error)}
for (i in 1:n){
for (j in 1:nrow(newX)){
spop[i,j]=uncureprob[j]*s0[i]+(1-uncureprob[j])
}
}
prd=cbind(spop=spop,Time=t)
}
structure(list(call=call,newuncureprob=uncureprob,prediction=prd),class="predictsmcure")
}
plotpredictsmcure <- function(object, type="S", xlab="Time",
ylab="Predicted Survival Probability",model=c("ph","aft"), ...)
{
pred <- object$prediction
if(model=="ph"){
pdsort <- pred[order(pred[,"Time"]),]
if(length(object$newuncureprob)==1) plot(pdsort[,"Time"],pdsort[,1], type="S")
else
matplot(pdsort[,"Time"],pdsort[,1:(ncol(pred)-1)],col=1,type="S",
lty=1:(ncol(pred)-1),xlab=xlab,ylab=ylab)
}
if(model=="aft"){
nplot=ncol(pred)/2
pdsort <- pred[order(pred[,1+nplot]),c(1,1+nplot)]
plot(pdsort[,2],pdsort[,1],xlab=xlab,ylab=ylab,col=1,type="S",ylim=c(0,1))
if(nplot>1){
for(i in 2:nplot){
pdsort<- pred[order(pred[,i+nplot]),c(i,i+nplot)]
lines(pdsort[,2],pdsort[,1],lty=i,type="S")
}
}
}
}
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Appendix B
Source Codes for NPHMC package
library(survival)
Sc<-function(t,accrualtime,followuptime,accrualdist){
if(accrualdist=="uniform") return((accrualtime+followuptime-t)/accrualtime)
if(accrualdist=="increasing") return((accrualtime+followuptime-t)^2/accrualtime^2)
if(accrualdist=="decreasing") return((1-(followuptime-t)^2/accrualtime^2))
}
f1<-function(t,survdist,k,lambda0){
if(survdist=="exp") {k=1; return(lambda0*k*(lambda0*t)^(k-1)*exp(-(lambda0*t)^k))}
if(survdist=="weib") {return(lambda0*k*(lambda0*t)^(k-1)*exp(-(lambda0*t)^k))}
}
f2<-function(t,accrualtime,followuptime,accrualdist,survdist,k,lambda0){
Sc(t,accrualtime,followuptime,accrualdist)*f1(t,survdist,k,lambda0)
}
H0<-function(t,survdist,k,lambda0){
if(survdist=="exp") {return(lambda0*t)}
if(survdist=="weib") {return((lambda0*t)^k)}
}
S0<-function(t,pi0,survdist,k,lambda0){
if(survdist=="exp") {k=1;return(pi0+(1-pi0)*exp(-(lambda0*t)^k))}
if(survdist=="weib") {return(pi0+(1-pi0)*exp(-(lambda0*t)^k))}
}
m<-function(t,beta0,gamma0,pi0,survdist,k,lambda0){
(gamma0/beta0+H0(t,survdist,k,lambda0))*pi0/S0(t,pi0,survdist,k,lambda0)-1}
f3<-function(t,beta0,gamma0,pi0,survdist,k,lambda0){
m(t,beta0,gamma0,pi0,survdist,k,lambda0)*f1(t,survdist,k,lambda0)
}
f4<-function(t,accrualtime,followuptime,accrualdist,beta0,gamma0,pi0,survdist,k,lambda0){
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m(t,beta0,gamma0,pi0,survdist,k,lambda0)*
f2(t,accrualtime,followuptime,accrualdist,survdist,k,lambda0)
}
NPHMC<-function(power=0.8,alpha=0.05,accrualtime,followuptime,p=0.5,
accrualdist=c("uniform","increasing","decreasing"),
hazardratio,oddsratio,pi0,survdist=c("exp","weib"),k=1,lambda0,data=NULL){
n<-list()
class(n) <- c("NPHMC")
if (is.null(data)){
if (hazardratio<=0) stop("Hazardratio must be greater than 0")
if (oddsratio<0) stop("Oddsratio cannot be less than 0")
if (pi0==0 | oddsratio==0) {
i1 <- integrate(f1,0,followuptime,survdist,k,lambda0)$value
i2 <- integrate(f2,followuptime,(accrualtime+followuptime),accrualtime,followuptime,
accrualdist,survdist,k,lambda0)$value
beta0 <- log(hazardratio)
pdeath <- i1+i2
nsizeph <- ceiling((qnorm(power)-qnorm(alpha/2))^2/(p*(1-p)*beta0^2*pdeath))
cat("====================================================================== \n")
cat("SAMPLE SIZE CALCULATION BASED ON STANDARD PH MODEL (NO CURE FRACTION) \n")
cat("====================================================================== \n")
cat("Standard PH Model: n =",nsizeph,"\n")}
else {
i1 <- integrate(f1,0,followuptime,survdist,k,lambda0)$value
i2 <- integrate(f2,followuptime,(accrualtime+followuptime),
accrualtime,followuptime,accrualdist,survdist,k,lambda0)$value
beta0 <- log(hazardratio)
gamma0 <- log(oddsratio)
i3 <- integrate(f3,0,followuptime,beta0,gamma0,pi0,survdist,k,lambda0)$value
i4 <- integrate(f4,followuptime,(accrualtime+followuptime),
accrualtime,followuptime,accrualdist,beta0,gamma0,pi0,survdist,k,lambda0)$value
nsize <- ceiling((qnorm(power)-
qnorm(alpha/2))^2*(i1+i2)/((i3+i4)^2*p*(1-p)*(1-pi0)*beta0^2))
pdeath <- i1+i2
nsizeph <- ceiling((qnorm(power)-qnorm(alpha/2))^2/(p*(1-p)*beta0^2*pdeath))
cat("\n")
cat("======================================================================== \n")
cat("SAMPLE SIZE CALCULATION FOR PH MIXTURE CURE MODEL AND STANDARD PH MODEL \n")
cat("======================================================================== \n")
cat("PH Mixture Cure Model: n =",nsize,"\n")
cat("Standard PH Model: n =",nsizeph,"\n")
n$nsize <- nsize }
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}
if (!is.null(data)){
ta=accrualtime
tf=followuptime
ttot=ta+tf
t<-data[,1]
colnames(data)<-c("Time","Status","X")
Time=data[,1]
Status=data[,2]
X=data[,3]
f=smcure(Surv(Time, Status)~X,~X,data=data,model="ph",Var=FALSE)
time<-sort(t[Status==1])
beta0nocure <- coxph(Surv(Time, Status)~X,method="breslow", data=data)$coef
death_point <- sort(unique(subset(Time, Status==1)))
coxexp <- exp(beta0nocure*X)
lambda <- numeric()
event <- numeric()
for(i in 1: length(death_point)){
event[i] <- sum(Status*as.numeric(Time==death_point[i]))
temp <- sum(as.numeric(Time>=death_point[i])*Status*drop(coxexp))
temp1 <- event[i]
lambda[i] <- temp1/temp
}
HHazard <- numeric()
for(i in 1:length(Time)){
HHazard[i] <- sum(as.numeric(Time[i]>=death_point)*lambda)
if(Time[i]>max(death_point))HHazard[i] <- Inf
if(Time[i]<min(death_point))HHazard[i] <- 0
}
snocure <- exp(-HHazard)
beta0 <- f$beta
print(beta0)
gamma0 <- -f$b[2]
pi0=1-exp(f$b[1])/(1 + exp(f$b[1]))
s=sort(f$s[Status==1],decreasing = TRUE)
snocure <- sort(snocure[Status==1],decreasing = TRUE)
f0<-diff(s)
f0nocure <- diff(snocure)
s1 <- sum(-f0*as.numeric(time<=tf)[-1])
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s1nocure <- sum(-f0nocure*as.numeric(time<=tf)[-1])
sc=(ta+tf-time)/ta
s2 <- sum(-diff(s)*sc[-length(sc)]*as.numeric(time>tf)[-1])
s2nocure <- sum(-diff(snocure)*sc[-length(sc)]*as.numeric(time>tf)[-1])
Spop=pi0+(1-pi0)*s
m=(gamma0/beta0-log(s))*pi0/Spop-1
s3 <- sum(-diff(s)*m[-length(m)]*as.numeric(time<=tf)[-1])
Spop4=pi0+(1-pi0)*s
m4=(gamma0/beta0-log(s))*pi0/Spop4-1
s4 <- sum(-diff(s)*m4[-length(m4)]*sc[-length(sc)]*
as.numeric((time>tf) & (time<=ttot))[-1])
nonpar=ceiling((qnorm(power)-qnorm(alpha/2))^2*(s1+s2)/((s3+s4)^2*p*(1-p)*(1-pi0)*beta0^2))
n$nonpar<- nonpar
n$HR <- exp(beta0)
n$OR <- exp(gamma0)
n$pi0<- pi0
cat("\n")
cat("======================================================================== \n")
cat("SAMPLE SIZE CALCULATION FOR PH MIXTURE CURE MODEL AND STANDARD PH MODEL \n")
cat("======================================================================== \n")
cat("PH Mixture Cure Model with KM estimators: n =",nonpar,"\n")
pdeathNonpar <- s1+s2
pdeathNonpar <- s1nocure+s2nocure
#cat("Probability of Death: p =",pdeathNonpar,"\n")
nonparPH <-
ceiling((qnorm(power)-qnorm(alpha/2))^2/(p*(1-p)*beta0nocure^2*pdeathNonpar))
cat("Standard PH Model with KM estimators: n =",nonparPH,"\n")
n$nonparPH<- nonparPH
}
}
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